TABLE OF CONTENTS
UNITED STATES


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a)
of the

Securities Exchange Act of 1934 (Amendment No. 1)

Filed by the Registrant  ¨

                        Filed by a Party other than the Registrant  ¨

Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:

¨Preliminary Proxy Statement
¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
xDefinitive Proxy Statement
¨Definitive Additional Materials
¨Soliciting Material Pursuant to §240.14a-12

GALENA BIOPHARMA,


Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to § 240.14a-12
SELLAS LIFE SCIENCES GROUP, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if other thanOther Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

xNo fee required.
¨Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)Title of each class of securities to which transaction applies:

(2)Aggregate number of securities to which transaction applies:

(3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)Proposed maximum aggregate value of transaction:

(5)Total fee paid:

¨Fee paid previously with preliminary materials.
¨Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)Amount Previously Paid:

(2)Form, Schedule or Registration Statement No.:

(3)Filing Party:

(4)Date Filed:


No fee required.

Fee previously paid with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

LOGO

NOTICE

TABLE OF SPECIAL MEETING OF STOCKHOLDERS

CONTENTS


[MISSING IMAGE: lg_sellaslifesciences-4clr.jpg]
April 29, 2024
To Be Held on October 21, 2016

September 21, 2016

Dear Galena Biopharma Stockholder,

Our Stockholders:

You are cordially invited to attend a special meetingthe 2024 Annual Meeting of Stockholders of SELLAS Life Sciences Group, Inc. (the “Special“Company”) to be held at 8:30 a.m. Eastern Time on June 20, 2024 (the “2024 Annual Meeting”), unless postponed or adjourned to a later date. We will hold the 2024 Annual Meeting virtually as a live webcast at www.virtualshareholdermeeting.com/SLS2024. You will not be able to attend the 2024 Annual Meeting in person. Please refer to the proxy materials for more information on how to access the 2024 Annual Meeting.
The enclosed Notice of Annual Meeting of Stockholders sets forth the proposals that will be presented at the 2024 Annual Meeting, which are described in more detail in the enclosed Proxy Statement. Our Board of Directors recommends that you vote “FOR” Proposals 1, 2, and 3 as set forth in the Proxy Statement.
Under Securities and Exchange Commission rules that allow companies to furnish proxy materials to stockholders over the Internet instead of a printed copy of proxy materials, we have elected to deliver our proxy materials to our stockholders over the Internet. This delivery process allows us to provide stockholders with the information they need, while at the same time conserving natural resources and lowering the cost of delivery. On or about May 3, 2024, we expect to mail to our stockholders a Notice of Internet Availability of Proxy Materials (the “Notice”), which contains instructions on how to access our Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2023. The Notice will also provide instructions on how to vote via the Internet as well as by telephone or mail.
We hope you will be able to attend the 2024 Annual Meeting. Whether you plan to attend the 2024 Annual Meeting or not, it is important that you cast your vote. When you have finished reading the Proxy Statement, we urge you to submit your vote so that your shares will be represented and voted at the 2024 Annual Meeting, whether or not you can attend.
On behalf of the Board and the management team, we thank you for your ongoing support of, and continued interest in, SELLAS Life Sciences Group, Inc.
Very truly yours,
[MISSING IMAGE: sg_angelosmstergiou-bw.jpg]
Angelos M. Stergiou, M.D., Sc.D. h.c.
President and Chief Executive Officer


TABLE OF CONTENTS

SELLAS LIFE SCIENCES GROUP, INC.
Times Square Tower, 7 Times Square, Suite 2503
New York, New York 10036
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To the Stockholders of SELLAS Life Sciences Group, Inc.:
You are invited to attend the 2024 Annual Meeting of Stockholders (“2024 Annual Meeting”) of Galena Biopharma,SELLAS Life Sciences Group, Inc., a Delaware corporation (the (“SELLAS,” “we,” “us,” “our,” or “Company”), which on June 20, 2024, at 8:30 a.m. Eastern Time. The 2024 Annual Meeting will be held exclusively online as a live webcast at www.virtualshareholdermeeting.com/SLS2024. There is no physical location for the 2024 Annual Meeting.
The 2024 Annual Meeting will be held for the following purposes, which are more fully described in the proxy statement accompanying this notice:
1.
To elect two (2) Class II directors to serve on October 21, 2016, at 9:00 a.m. local time, at 2010 Crow Canyon Place, Suite 130, San Ramon, CA 94583. our Board of Directors for a three-year term expiring on the date on which our annual meeting of stockholders is held in 2027;
2.
To ratify the appointment by our Audit Committee of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and
3.
To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
In addition, stockholders may be asked to consider and vote upon such other business as may be properly brought before the meeting and any adjournment or postponement thereof.
Only stockholders who heldof record of SELLAS common stock at the close of business on April 25, 2024, the record date, September 9, 2016 (the “Record Date”), may vote at the Special Meeting, including any adjournment or postponement thereof.

We are holding the Special Meeting for the following purposes, which are described in more detail in our Proxy Statement:

(1)To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation (as amended from time to time, the “Charter”), to effect a reverse stock split of the outstanding shares of the Company’s common stock, par value $0.0001 per share (the “common stock”), at a ratio of not less than 1 for 2 and not greater than 1 for 20, with the exact ratio and effective time of the reverse stock split to be determined by the Board of Directors (the “Reverse Stock Split”) and publicly announced by press release.
(2)To authorize the issuance shares of the Company’s common stock issuable upon the redemption, conversion or other satisfaction of the Company’s obligations under its Amended and Restated 9% Original Issue Discount Senior Secured Debenture due November 10, 2018, without the need for any limitation or cap on issuances as required by and in accordance with NASDAQ Marketplace Rule 5635(d).
(3)To authorize the adjournment of the Special Meeting, if necessary or appropriate, if a quorum is present, to solicit additional proxies if there are insufficient votes at the Special Meeting in favor of the Reverse Stock Split; and
(4)To transact any other business that may properly come before the Special Meeting.

We are focused on continuing to advance our existing pipeline of drug candidates including GALE-401 (Anagrelide Controlled Release) and supporting our ongoing immunotherapy programs with NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. We believe GALE-401, targeting an unmet medical need, represents a potentially significant commercial opportunity with a streamlined clinical and regulatory development path. As such, we are actively preparing to advance this program into a Phase 3 Pivotal trial expected to initiate in the first half of 2017. The ongoing combination trials with NeuVax are progressing well with the presentation of safety data in our NeuVax plus trastuzumab combination trial in the HER2 1+/2+ patient population in the fourth quarter. And, we continue to evaluate the appropriate indications and patient populations to advance the asset. Additionally, we look forward to data presentations for GALE-301 this year. Corporate development activities remain a focus as we seek to expand our existing pipeline and seek partnering opportunities for our existing drug candidates that can increase shareholder value and help patients living with diseases in areas of unmet medical need.

The accompanying Proxy Statement more fully describes the details of the business to be conducted at the Special Meeting. After careful consideration, our Board of Directors has unanimously approved the proposals and recommends that you vote FOR each proposal described in the Proxy Statement. Your vote at the Special Meeting is important. Whether or not you plan to attend the Special Meeting, please vote as soon as possible by Internet, telephone or mail as described in the accompanying Proxy Statement.

On behalf of our entire Board of Directors, we thank you for your continued support.

Sincerely,

LOGO

Mark W. Schwartz, Ph.D.

President & Chief Executive Officer

1


GALENA BIOPHARMA, INC.

2000 Crow Canyon Place, Suite 380

San Ramon, CA 94583

(925) 498-7709

PROXY STATEMENT

For the Special Meeting of Stockholders

To Be Held On October 21, 2016

Items of Business

This proxy statement (“Proxy Statement”) and the enclosed proxy card are being furnished in connection with the solicitation of proxies by the Board of Directors of Galena Biopharma, Inc. (the “Company” or “Galena”) for use at the Special Meeting of Stockholders (“Special Meeting”) and any adjournment or postponement thereof. Your proxies will be voted in accordance with your instructions. If no choice is specified, the proxies will be voted as recommended by our Board of Directors. A stockholder who signs a proxy may revoke or revise that proxy at any time before the Special Meeting. Please see “Revocation of Proxy” below for more information on how to revoke a proxy. This Proxy Statement will be provided electronically, if elected, or otherwise is being mailed on or about September 22, 2016 to stockholders of record at the close of business on September 9, 2016 (the “Record Date”).

We are holding the Special Meeting for the following purposes, which are described in more detail in this Proxy Statement:

Proposal No. 1 — To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation (as amended from time to time, the “Charter”), to effect a reverse stock split of the Company’s common stock, at a ratio of not less than 1 for 2 and not greater than 1 for 20, with the exact ratio and effective time of the reverse stock split to be determined by the Board of Directors and publicly announced in a press release. This proposal must be approved by a majority of the outstanding shares of our common stock. As a result, abstentions and broker non-votes will have the same effect as a vote against such proposal.

Proposal No. 2 — To authorize the issuance of shares of the Company’s common stock issuable upon the redemption, conversion or other satisfaction of the Company’s obligations under its Amended and Restated 9% Original Issue Discount Senior Secured Debenture due November 10, 2018 in the principal amount of $25,530,000, without the need for any limitation or cap on issuances as required by and in accordance with NASDAQ Marketplace Rule 5635(d). This proposal must be approved by a majority of the votes properly cast on the matter affirmatively or negatively. As a result, abstentions and broker non-votes will be entirely excluded from the vote and will have no effect on its outcome.

Proposal No. 3 — To authorize adjournment of the Special Meeting, if necessary or appropriate to solicit additional proxies if there are insufficient votes at the Special Meeting in favor of the Reverse Stock Split (the “Adjournment Proposal”). This proposal must be approved by a majority of the votes properly cast on the matter affirmatively or negatively. As a result, abstentions and broker non-votes will be entirely excluded from the vote and will have no effect on its outcome.

To conduct any other business properly brought before the Special Meeting.

Record Date:

Only those stockholders of record at the close of business on September 9, 2016 are entitled to notice of and to vote at the Special2024 Annual Meeting eitherand at any adjournments or postponements thereof. A list of stockholders of record will be available at the 2024 Annual Meeting and, during the 10 days prior to the annual meeting, at our principal executive offices located at Times Square Tower, 7 Times Square, Suite 2503, New York, New York 10036.

Important Notice Regarding Internet Availability of Proxy Materials for the Annual Meeting to be Held on June 20, 2024:   SELLAS’ Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”) are available at www.proxyvote.com. To access these proxy materials, please follow the instructions found on your Notice of Internet Availability of Proxy Materials (the “Notice”) or proxy card.
Your vote is important regardless of the number of shares of common stock you own. Whether or not you expect to attend the 2024 Annual Meeting, please submit your proxy by Internet, telephone, or mail by following the instructions found on the Notice or proxy card so that your shares of common stock may be represented and voted at the 2024 Annual Meeting.
Regardless of the number of shares of common stock of the Company that you own, your vote is important. Thank you for your continued support, interest and investment in personthe Company.
By Order of the Board of Directors,
[MISSING IMAGE: sg_angelosmstergiou-bw.jpg]
Angelos M. Stergiou, M.D., Sc.D. h.c.
President and Chief Executive Officer
New York, New York
April 29, 2024


TABLE OF CONTENTS

TABLE OF CONTENTS
Page
2
9
11
11
13
14
14
14
15
15
22
22
23
27
31
32
32
33
34
35
35
36
37
39

i

TABLE OF CONTENTS

SELLAS LIFE SCIENCES GROUP, INC.
Times Square Tower, 7 Times Square, Suite 2503
New York, New York 10036
PROXY STATEMENT
FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON
Thursday, June 20, 2024 at 8:30 a.m. (Eastern Time) via Live Webcast
In this Proxy Statement, “SELLAS,” the “Company,” “we,” “us,” and “our” refer to SELLAS Life Sciences Group, Inc., unless the context otherwise provides.
The 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) to be held on Thursday, June 20, 2024, beginning at 8:30 a.m. Eastern Time, will be held exclusively online via the Internet as a virtual webcast at: www.virtualshareholdermeeting.com/SLS2024. There will not be a physical meeting location.
Only stockholders of record at the close of business on April 25, 2024 (the “Record Date”) will be entitled to vote at the 2024 Annual Meeting. The Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access this Proxy Statement and the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (“2023 Annual Report”) is first being mailed to stockholders of record on or about May 3, 2024.
You may attend the 2024 Annual Meeting live online by proxy.

There are several waysvisiting www.virtualshareholdermeeting.com/SLS2024, where you will be able to vote. Whatever methodlisten to the meeting live, submit questions, and vote online. The webcast will start at 8:30 a.m. Eastern Time, on June 20, 2024. To attend the 2024 Annual Meeting, vote online, and submit questions during the Annual Meeting, you will need the control number included in your Notice, voting instruction form, or proxy card. You may also attend the virtual meeting website as a “Guest.” Online access will open approximately 15 minutes before the start of the 2024 Annual Meeting. If you choose votingto request paper copies of proxy materials, the instructions for doing so can be found on the Notice and proxy card.

If you wish to submit a question before the meeting, you may send your question, along with proof of ownership of our common stock, to annualmeeting@sellaslife.com. Registered stockholders and beneficial owners may submit a question in writing during the 2024 Annual Meeting through the virtual meeting website. If you join the virtual meeting as a “Guest,” you will not be permitted to ask a question during the meeting. Our virtual meeting will be governed by our Annual Meeting Rules of Conduct, which will be posted at www.proxyvote.com in advance of the Special Meeting will ensure that your sharesmeeting.
Holders of our common stock at the close of business on April 25, 2023 will be voted as you direct, even if you do not attendentitled to vote at the Special2024 Annual Meeting. Voting instructions are detailed on the following page and are included on the proxy card enclosed with our Proxy Statement.

Materials:

Enclosed is our Proxy Statement as filed with the Securities and Exchange Commission (“SEC”). These materials are also available under the Investors section of our website:www.galenabiopharma.com, and the SEC’s website atwww.sec.gov, or will be furnished without charge to any stockholder upon written or oral request to Galena Biopharma, Inc., Attn: Corporate Secretary, 2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583; telephone: (925) 498-7709. Information on our website is not incorporated by reference in this Proxy Statement.

2


If you plan to attend the Special Meeting, Galena representatives will be onsite to assist with registration for the event. You must bring proof of your identity to the Special Meeting. If your shares are registered in the name of a bank, broker, or other holder of record, please bring both a photo ID and documentation of your stock ownership as of September 9, 2016 (such as a brokerage statement).

Voting Information, Voting Securities, Quorum, and Votes Required

As a stockholder, it is very important that you vote. Please carefully review this Proxy Statement and follow the instructions below to cast your vote on all of the proposals. As of the Record Date, 214,481,939April 25, 2024, 57,754,928 shares of our common stock were issued and outstanding. Eachoutstanding and entitled to vote. Stockholders are entitled to one vote for each share of common stock entitles the holder to one vote with respect to each matter submitted to stockholders at the Special Meeting. Stockholders do not have cumulative voting rights. We have no other securities entitled to vote at the Special Meeting.

The representation in personheld. A majority, or by proxy28,877,465, of at least a majority in voting power of the shares of common stock issued, outstanding and entitled to vote at the Special Meeting is necessary to establish a quorum for the transaction of business. If a quorum is not present, the meeting will be adjourned until a quorum is obtained.

The approval of the Reverse Stock Split requires the affirmative vote of the majority of all outstanding shares. A representative of our Company will serve as the inspector of elections at the Special Meeting. The approval of the issuance of common stock for the redemption and/or conversion of the debenture and warrants as described in Proposal No. 2 requires the affirmative vote of the majority ofthese shares, present in person or represented by proxy and voting on such matters at the Special Meeting.

Shares that abstain from voting as to2024 Annual Meeting, will constitute a particular matter will be countedquorum for the purposetransaction of determining whetherbusiness.

The Notice of Annual Meeting of Stockholders, this Proxy Statement, our 2023 Annual Report and the proxy card are also available on the Internet. Web links and addresses contained in this Proxy Statement are provided for convenience only, and the content on the referenced websites does not constitute a quorum exists. However,part of this Proxy Statement.

1

TABLE OF CONTENTS

QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING
Why is the Company soliciting my proxy?
Our Board of Directors (the “Board”) is soliciting your proxy to vote at the 2024 Annual Meeting to be held via live webcast, on June 20, 2024, at 8:30 a.m., Eastern Time, and any adjournments or postponements of the meeting. This Proxy Statement, along with respectthe accompanying Notice of Annual Meeting of Stockholders, summarizes the purposes of the meeting and the information you need to Proposal No. 1 – Approvalknow to vote at the 2024 Annual Meeting.
We intend to commence distribution of Amendmentthe Important Notice Regarding the Availability of Proxy Materials (the “Notice”) to Amendedstockholders on or about May 3, 2024, which, together with this Proxy Statement, the proxy card, and Restated Certificatea copy of Incorporationthe 2023 Annual Report, are referred to Effectas proxy materials. The proxy materials are available online at www.proxyvote.com.
You received the Notice because you owned shares of our common stock on April 25, 2024 (the “Record Date”).
Why did I receive a Reverse Stock Split, an abstentionnotice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials?
As permitted by the rules of the U.S. Securities and Exchange Commission (the “SEC”) we may furnish our proxy materials to our stockholders by providing access to such documents on the Internet, rather than mailing printed copies of these materials to each stockholder. Stockholders will havenot receive printed copies of the same effect as an “Against” vote. Shares heldproxy materials unless they request them. We believe that this process will expedite stockholders’ receipt of proxy materials, lower the costs of the 2024 Annual Meeting and help to conserve natural resources. If you received the Notice by mail or electronically, you will not receive a printed or email copy of the proxy materials, unless you request one by following the instructions included in “street name”the Notice. Instead, the Notice provides instructions on how you may access and review all of the proxy materials and submit your proxy via the Internet. If you requested a paper copy of the proxy materials, you may authorize the voting of your shares by brokers, banksfollowing the instructions on the proxy card, in addition to the other methods of voting described in this Proxy Statement.
What proxy materials are available on the Internet?
This Proxy Statement and the 2023 Annual Report are available online at www.proxyvote.com. The Notice and proxy card contain additional information on how to access the proxy materials online or other nominees who indicateto request a paper copy.
How do I attend the 2024 Annual Meeting?
To attend the virtual 2024 Annual Meeting, visit www.virtualshareholdermeeting.com/SLS2024 on theirJune 20, 2024 and follow the instructions included on your proxy cards that theycard, your Notice, or voting instruction card. The meeting will begin promptly at 8:30 a.m. Eastern Time on June 20, 2024. We encourage you to access the meeting prior to the start time. Online access opens at approximately 15 minutes before the start of the annual meeting. If you do not have discretionary authorityyour proxy card, Notice, or voting instruction card, you may join as a “Guest,” but you will not be able to vote such shares as to a particular matter, which we refer to as “broker non-votes,”or ask questions.
Who may vote at the 2024 Annual Meeting?
Only stockholders of record at the close of business on the Record Date will be countedentitled to vote at the 2024 Annual Meeting. On the Record Date, there were 57,754,928 shares of common stock issued and outstanding. Our common stock is our only class of voting stock.
A list of our stockholders of record will be open for examination by any stockholder beginning 10 days prior to the purpose of determining whether2024 Annual Meeting at our headquarters located at 7 Times Square, Suite 2503, New York, NY 10036. If you would like to view the list, please contact our Corporate Secretary to schedule an appointment by writing to the Corporate Secretary at the address above. In addition, the list will be available

2

TABLE OF CONTENTS

for inspection by stockholders on the virtual meeting website during the Annual Meeting. Those who join the virtual annual meeting as a quorum exists but“Guest” will not have any effect uponbe able to view the outcomelist of votingstockholders of record.
Stockholder of record:   If, on the Record Date, your shares of SELLAS common stock were registered directly in your name with respect to matters voted onour transfer agent, Computershare Investor Services, then you are a stockholder of record. As stockholder of record, you may vote live online at the Special2024 Annual Meeting except for Proposal No. 1 – Approvalor by proxy.
Beneficial holder or street name holder:   If, on the Record Date, your shares of Amendment to Amended and Restated Certificate of Incorporation to EffectSELLAS common stock were held in an account by an intermediary, such as a Reverse Stock Split where they willbank, broker, or other agent, then you are the beneficial holder or street name holder. You should have received the proxy materials or Notice from your bank, broker, or other agent. As a beneficial holder, you have the same effectright to direct your bank, broker, or other agent on how to vote your shares. Please follow the instructions provided by your bank, broker, or other agent on how to vote, or contact your broker, bank, or other agent to request a proxy form.
How do I submit questions?
You may submit questions in advance of the 2024 Annual Meeting by emailing the question, along with proof of stock ownership, to annualmeeting@sellaslife.com prior to 5:00 p.m. Eastern Time on Wednesday, June 19, 2024. If you are a stockholder of record, you may also submit questions during the 2024 Annual Meeting by visiting: www.virtualshareholdermeeting.com/SLS2024. We will, subject to time constraints, answer all questions that are pertinent to the business of the 2024 Annual Meeting and will give priority to questions submitted in advance. If you attend the 2024 Annual Meeting as an “Against” vote. Brokers holdinga “Guest,” then you will not be permitted to submit questions during the meeting.
How do I vote?
Whether you plan to attend the 2024 Annual Meeting or not, we urge you to vote by proxy. All shares for clients who haverepresented by valid proxies that we receive through this solicitation, and that are not givenrevoked, will be voted in accordance with your instructions on the proxy card or as instructed via the Internet or telephone. If you properly submit a proxy without giving specific voting instructions, are permitted to vote in their discretion only with respect to Proposal No.2 – Authorize Issuance of Common Stock for Conversion of Debenture and Proposal No.3 – Approval of Adjournment of the Special Meeting.

Stockholders may vote in person or by proxy. Voting by proxy will not in any way affect a stockholder’s right to attend the Special Meeting and vote in person. Any stockholder voting by proxy has the right to revoke the proxy at any time before the polls close at the Special Meeting by giving our corporate secretary a duly executed proxy card bearing a later date than the proxy being revoked at any time before that proxy is voted or by appearing at the Special Meeting and voting in person. The shares represented by all properly executed proxies received in time for the Special Meeting will be voted as specified. If the shares you own are held in your name and you do not specify in the otherwise properly executed proxy card how your shares are to be voted, they will be voted in accordance with our Board of Directors’ recommendations. If any other matters properly come beforerecommendations as noted below. Voting by proxy will not affect your right to attend the meeting,2024 Annual Meeting.

To cast your vote before the persons named in the accompanying proxy intend to2024 Annual Meeting, you may vote or otherwise act, in accordance with their judgment. If the shares you own are held in “street name,” the broker, bank or other nominee, as the record holder of your shares, is required to vote your shares in accordance with your instructions. In order to vote your shares held in “street name,” you will need to follow the directions that your broker, bank or other nominee provides to you.

Householding

The SEC has adopted rules that permit companies and intermediaries, such as brokers, to satisfy delivery requirements for Special Meeting materials with respect to two or more stockholders sharing the same address by delivering a single set of Special Meeting materials addressed to those stockholders. This process, commonly referred to as “householding,” potentially provides extra convenience for stockholders and cost savings for companies. Because we utilize the “householding” rules for Special Meeting materials, stockholders who share the same address will receive only one copy of the Special Meeting materials, unless we receive contrary instructions from any stockholder at that address. If you prefer to receive multiple copies of the Special Meeting materials at the same address you share with other stockholders, additional copies will be provided to you promptly upon request. following methods:

[MISSING IMAGE: ic_internet-bw.jpg]
By Internet:   Please follow the instructions on the proxy card or voting instructions sent to you. Your vote must be received by 11:59 p.m. Eastern Time on Wednesday, June 19, 2024, to be counted.
[MISSING IMAGE: ic_tele-bw.jpg]
By Telephone:   To vote over the telephone, dial the number listed on the proxy card or voting instructions sent to you, and follow the instructions. Your vote must be received by 11:59 p.m. Eastern Time on Wednesday, June 19, 2024, to be counted.
[MISSING IMAGE: ic_mail-bw.jpg]
By Proxy by Mail:   Mark, sign, and date your proxy card and mail the proxy to the address stated on the proxy card. If you return your signed proxy card to us before the 2024 Annual Meeting, we will vote your shares as you direct.
If you are a stockholder of record, you may also cast your vote during the 2024 Annual Meeting by accessing the annual meeting website and following the instructions on the Notice or proxy card.
If you are a beneficial holder, you should have received voting instructions from the bank, broker, or other agent. Follow the voting instructions you received from that intermediary to ensure that your vote is counted. To vote during the 2024 Annual Meeting, you must obtain additional copies ata valid proxy from your bank, broker, or other agent. Follow the same addressinstructions from your bank, broker, or other agent included with the proxy materials, or contact your bank or broker to request a proxy form.
If you share with other stockholders by calling us at (925)

3


498-7709 or upon written requestattend the annual meeting online as a “Guest,” you will not be able to Galena Biopharma, Inc., Attn: Corporate Secretary, 2000 Crow Canyon Place, Suite 380, San Ramon, California 94583. Eligible stockholderscast your vote during the 2024 Annual Meeting.


3

TABLE OF CONTENTS

What is the difference between holding shares as a stockholder of record receiving multiple copiesand as a beneficial holder/owner?
If, on the Record Date, your shares were registered directly in your name with our transfer agent, Computershare, then you are a stockholder of record. If, on the SpecialRecord Date, your shares were not held in your name, but rather in an account at a brokerage firm, bank or other similar organization, then you are the beneficial owner of shares held in “street name.”
Stockholder of Record: Shares Registered in Your Name
If you are a stockholder of record, you may vote during the 2024 Annual Meeting, materials can request householdingvote by contacting usproxy over the telephone or through the Internet, or vote by proxy using a proxy card.
Beneficial Owner: Shares Registered in the same manner. Name of Broker, Bank or Other Nominee
If you are a beneficial owner and hold yourof shares registered in a brokerage or custody account, you can request additional copiesthe name of the Special Meeting materials at the same address you share with other stockholders or you can request householding by notifying your broker, bank, or other nominee.

4


Voting Information

Asintermediary, you should have received a stockholder, it is very importantvoting instruction form with the proxy materials from that you vote. Please carefully review this Proxy Statement andorganization rather than from us. To vote prior to the 2024 Annual Meeting, follow the instructions below to cast your vote on all of the proposals.

Voter Eligibility

Only those stockholders of record at the close of business on September 9, 2016 are entitled to notice of and to vote at the Special Meeting or any postponement or adjournment thereof. A complete list of stockholders entitled to vote at the Special Meeting will be available for examination at the Special Meeting for any purpose germane to the Special Meeting.

How to Vote

Even if you plan to attend the Special Meeting, if your shares are registered directly in your name, please vote right away using one of the following advance voting methods.Make sure to have your proxy card in hand and follow the instructions.

LOGO

By Internet If you have Internet access, you may submit your proxy from any location in the worldprovided by following the Internet voting instructions on the proxy card or voting instruction card sent to you.

LOGO

By Telephone You may submit your proxy by following the telephone voting instructions on the Notice of Internet Availability you received or by following the telephone voting instructions on the proxy card or voting instruction card sent to you.

LOGO

By Mail You may do this by marking, dating and signing your proxy card or, for shares held in street name, the voting instruction card provided to you by your broker or nominee, and mailing it in the enclosed, self-addressed, postage prepaid envelope. No postage is required if mailed in the United States. Please note that you will be mailed a printed proxy card or printed voting instruction card only if you request that such printed materials be sent to you by following the instructions in the Notice of Internet Availability for requesting paper copies of the proxy materials.

All stockholders of record may vote in person at the Special Meeting.If your shares are held in “street name” for your account by a broker, bank or other nominee, you will receive instructions from your broker, bank, or other nominee explaining how to vote.nominee. If you plan to vote in person at the Special Meeting, you should contact the broker, bank or other nominee that holdsare a beneficial owner, your shares to obtain a broker’s proxy card and bring it with you to the Special Meeting. A broker’s proxy card is not the form of proxy card enclosed with this Proxy Statement. You will not be able to vote shares you hold in “street name” at the Special Meeting unless you have a proxy card from your broker issued in your name giving you the right to vote the shares.

Your proxy will be voted according to your instructions. If you do not specify how you want your shares voted, they will be voted in accordance with our Board of Directors’ recommendations.

Electronic Document Delivery

We are pleased to take advantage of SEC rules that allow companies to furnish their proxy materials over the Internet. We are mailing to many of our stockholders a Notice of Internet Availability of Proxy Materials (“Notice”) instead of a paper copy of our proxy materials. The Notice contains instructions on how to access those documents and to castdeadline for submitting your vote viabefore the Internet, as described above. The Notice also contains instructions on how to request a paper copy of our proxy material. All stockholders who do not receive a Notice will receive a paper copy of the proxy materials by mail. This process allows us to provide our stockholders with the information they need on a more timely basis, while reducing the environmental impact and lowering the costs of printing and distributing our proxy materials.

5


Proxy Summary

This summary highlights information contained elsewhere in this Proxy Statement. This summary does not contain all of the information that you should consider and you should read this entire Proxy Statement before voting.

Stockholders are being asked to vote on the following matters:

Our Board of Director’s
Recommendation

Proposal 1: Approval of Amendment to Amended and Restated Certificate of Incorporation to Effect the Reverse Stock SplitFOR
Our Board of Directors has determined that, in connection with maintaining our NASDAQ listing, it is in the best interest of the Company, and in the best interest of our stockholders, to amend our Amended and Restated Certificate of Incorporation to effect a reverse stock split within the range of 1:2 to 1:20 with the final decision of whether to proceed with the Reverse Stock Split, the effective time of the Reverse Stock Split, and the exact ratio of the Reverse Stock Split to be determined by the Board of Directors, in its discretion. If the stockholders approve the Reverse Stock Split, and the Board of Directors decides to implement it, the Reverse Stock Split will become effective as of 12:01 a.m., Eastern Time on a date to be determined by the Board of Directors that will be specified in the Certificate of Amendment. If the Board of Directors does not decide to implement the Reverse Stock Split within twelve months from the date of the Special Meeting, the authority granted in this proposal to implement the reverse stock split will terminate.
Proposal 2: Authorize the Issuance of Common Stock for Redemption and/or Conversion of DebentureFOR

In May 2016, we secured a debt financing with JGB (Cayman) Newton Limited (“JGB”) with terms that included a 6.375% original issue discount, a 9% Senior Secured Debenture due November 10, 2018 (as amended, “Debenture”). We amended the Debenture in August 2016 to allow us to repay the Debenture under certain conditions with our common stock and allow the holder of the Debenture to convert some or all of the Debenture into stock under certain conditions. The flexibility to repay this Debenture in either cash or shares of our common stock, together with other financing facilities we have established, provide us with the necessary means and flexibility to fund our operations. If we decide to pay the Debenture in shares and/or the holder of the Debenture decides to convert the Debenture into our common stock, we may deliver to the holder of the Debenture our common stock in excess of 19.99% of our outstanding shares, thus requiring shareholder approval. As a result, our Board of Directors have determined that it is in the best interest of the Company, and in the best interest of our stockholders, to obtain the requisite stockholder approval to authorize the issuance of shares of our common stock equal to 20% or more of our common stock or 20% or more of our voting power outstanding prior to the sale for less than the greater of book or market value of the stock (the “20% Cap”) to allow us to make the monthly redemptions in shares of our common stock, allow JGB to equitize some or all of the Debenture through a conversion of the outstanding balance of the debt and/or allow the issuance of shares upon the exercise by JGB of the warrants.

Proposal 3: Approval of AdjournmentFOR
Our Board of Directors has determined that obtaining the necessary affirmative votes for Proposals No. 1 and No. 2 are in the best interest of stockholders and so an adjournment, postponement or continuance to obtain such affirmative votes is justified.

6


Proposal No. 1

Reverse Stock Split

Approval of Amendment to Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split

General

Our Board of Directors has unanimously approved, and recommended that our stockholders approve, an amendment to our Charter (the “Certificate of Amendment”), to effect a reverse stock split at a ratio of not less than1-for-2 and not greater than1-for-20, with the final decision of whether to proceed with the Reverse Stock Split, the effective time of the Reverse Stock Split, and the exact ratio of the Reverse Stock Split to be determined by the Board of Directors, in its discretion. If the stockholders approve the Reverse Stock Split, and the Board of Directors decides to implement it, the Reverse Stock Split will become effective as of 12:01 a.m.2024 Annual Meeting is 11:59 p.m. Eastern Time on a date to be determined by the Board that will be specified in the Certificate of Amendment. If the Board of Directors does not decide to implement the Reverse Stock Split within twelve months from the date of the Special Meeting, the authority granted in this proposal to implement the reverse stock split will terminate.

The Reverse Stock Split will be realized simultaneously for all outstanding common stock, options to purchase shares of our common stock (including shares available for future grants under the 2016 Incentive Plan), and warrants to purchase shares of our common stock. The Reverse Stock Split will affect all holders of common stock uniformly and each stockholder will hold the same percentage of common stock outstanding immediately following the Reverse Stock Split as that stockholder held immediately prior to the Reverse Stock Split, except for immaterial adjustments that may result from the treatment of fractional shares as described below. The Reverse Stock Split will not change the par value of our common stock and will not reduce the number of authorized shares of common stock.

If we fail to obtain stockholder approval of either Proposal No.1 or Proposal No.2 (described in the next section) at the Special Meeting, we intend to continue to seek to obtain stockholder approval at each subsequent annual meeting of stockholders and/or special meetings of stockholders until such approval has been obtained and we will incur the costs associated therewith.

Reasons for the Reverse Stock Split

Retain Listing on the NASDAQ Capital Market

The principal reason for the reverse stock split is the continued listing on The NASDAQ Capital Market by increasing the per share trading price of the Company’s common stock in order to help ensure a share price high enough to satisfy the $1.00 per share minimum bid price requirement, although there can be no assurance that the trading price of our common stock would be maintained at such level or that we will be able to maintain the listing of our common stock on The NASDAQ Capital Market under the ticker symbol “GALE”.

As previously reported, on August 11, 2016, the Company received written notice (the “Notification Letter”) from the NASDAQ Stock Market (“NASDAQ”) notifying the Company that it was not in compliance with the minimum bid price requirements set forth in NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market, because the bid price of the Company’s common stock had closed below the minimum $1.00 per share for the 30 consecutive business days prior to the date of the Notification Letter. NASDAQ stated in its August 11th letter that, in accordance with Marketplace Rule 5810(c)(3)(A), we have been provided a grace period of 180 calendar days, or until February 7, 2017, in which to regain compliance with the minimum consolidated closing bid price requirement for continued listing. Compliance will be regained if our consolidated closing bid price is at or above $1.00 for at least 10 consecutive trading days anytime during the 180-day period.

The Board of Directors believes that maintaining the listing of our common stock on the NASDAQ Capital Market is in the Company’s best interests and the best interests of our stockholders. The Board of Directors has considered the potential harm to the Company and our stockholders should NASDAQ delist our common stock. Delisting from NASDAQ would significantly affect the ability of investors to trade our securities and would likely adversely affect our ability to raise additional financing through the public or private sale of equity securities. Delisting would also likely negatively affect the value and liquidity of our common stock because alternatives, such as the OTC Bulletin Board and the pink sheets, are generally considered to be less efficient markets.

We believe that the decrease in the number of shares of our outstanding common stock as a consequence of the Reverse Stock Split, and the anticipated increase in the price per share, is necessary to ensure that we retain listing on the NASDAQ Capital Market as well as encouraging greater interest in our common stock by the financial community, business development partners and the investing

7


public. We believe it will also help us attract and retain employees and other service providers, help us raise additional capital through the sale of stock in the future if needed, and possibly promote greater liquidity for our stockholders with respect to those shares presently held by them.

We believe that the Company’s best option to meet NASDAQ’s $1.00 minimum bid price requirement of Marketplace Rule 5810(c)(3)(A) may be to effect the Reverse Stock Split to increase the per share trading price of our common stock. The volatility and fluctuations in the capital markets combined with the potential news items related to clinical and operational updates, may not increase our stock price by a sufficient amount to meet the NASDAQ listing requirements within the 180-day grace period without the Reverse Stock Split.

Marketability

In addition, we believe that the low per share market price of our common stock impairs its marketability to and acceptance by institutional investors and other members of the investing public and creates a negative impression of the Company. Many investors, brokerage firms and market makers consider low priced stocks as unduly speculative in nature and, as a matter of policy, avoid investment and trading in such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide coverage of lower priced stocks. The presence of these factors may adversely affect not only the pricing of our common stock but also its trading liquidity. In addition, these factors may affect our ability to raise additional capital through the sale of stock.

Because of the trading volatility often associated with low-priced stocks, many brokerage firms and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. Some of those policies and practices pertain to the payment of brokers’ commissions and to time-consuming procedures that function to make the handling of lower-priced stocks unattractive to brokers from an economic standpoint. Additionally, because brokers’ commissions on lower-priced stocks generally represent a higher percentage of the stock price than commissions on higher-priced stocks, the current share price of the common stock can result in an individual stockholder paying transaction costs that represent a higher percentage of total share value than would be the case if our share price were substantially higher. This factor may also limit the willingness of institutions to purchase our common stock. The Board of Directors believes that the anticipated higher market price resulting from a Reverse Stock Split could enable institutional investors and brokerage firms with such policies and practices to invest or handle trading in our common stock, but there can be no assurance that the Reverse Stock Split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks.

We believe that our current low stock price may prevent or discourage investment in our pipeline programs. We are focused on continuing to advance our existing pipeline of drug candidates including GALE-401 (Anagrelide Controlled Release) and supporting our ongoing immunotherapy programs with NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. We believe GALE-401, targeting an unmet medical need, represents a potentially significant commercial opportunity with a streamlined clinical and regulatory development path. As such we are actively preparing to advance this program into a Phase 3 Pivotal trial expected to initiate in the first half of 2017. The ongoing combination trials with NeuVax are progressing well with the presentation of safety data in our NeuVax plus trastuzumab combination trial in the HER2 1+/2+ patient population in the fourth quarter. And, we continue to evaluate the appropriate indications and patient populations to advance the asset. Additionally, we look forward to data presentations for GALE-301 this year. Corporate development activities remain a focus as we seek to expand our existing pipeline and seek partnering opportunities for our existing drug candidates that can increase shareholder value and help patients living with diseases in areas of unmet medical need.

Further, we believe that a higher stock price could help us establish business development relationships with other companies. We believe that potential business development partners may be less confident in the prospects of a company with a low stock price, and are less likely to enter into business relationships with a company with a low stock price. If the Reverse Stock Split successfully increases the per share price of our common stock, we believe this may increase our ability to attract business development partners. Also, we believe that strategic transactions are more likely without a low stock price. With a successful reverse stock split, in theory, we may be more successful in engaging in strategic transactions including mergers and acquisitions.

We further believe that a higher stock price could help us attract and retain employees and other service providers. We believe that some potential employees and service providers are less likely to work for a company with a low stock price, regardless of the size of the company’s market capitalization.

With shares trading at a higher price, it may promote greater liquidity for our stockholders with respect to those shares presently held by them. However, the possibility also exists that liquidity may be adversely affected by the reduced number of shares which would be outstanding if the Reverse Stock Split is effected, particularly if the price per share of our common stock begins a declining trend after the Reverse Stock Split is effected.

8


If Proposal No. 1 is not approved by our stockholders and implemented, approval by our stockholders of this Proposal No. 2 will have no effect as we will not have enough authorized shares to accommodate the monthly redemptions, conversion of the Debenture or exercise of the Warrants, as applicable, and because we would not have obtained the required Stockholder Approval (described below).

The Board of Directors believes that stockholder adoption of a range of Reverse Stock Split ratios (as opposed to adoption of a single reverse stock split ratio or a set of fixed ratios) provides maximum flexibility to achieve the purposes of a reverse stock split and, therefore, is in the best interests of the Company. In determining a ratio following the receipt of stockholder adoption, the Board of Directors (or any authorized committee of the Board of Directors) may consider, among other things, factors such as:

the historical trading price and trading volume of our common stock;
the number of shares of our common stock outstanding;
the then prevailing trading price and trading volume of our common stock and the anticipated impact of the Reverse Stock Split on the trading market for our common stock;
the anticipated impact of a particular ratio on our ability to reduce administrative and transactional costs;
the continued listing requirements of NASDAQ; and
prevailing general market and economic conditions.

The Board of Directors (or any authorized committee of the Board of Directors) reserves the right to elect to abandon the Reverse Stock Split, notwithstanding stockholder adoption thereof, if it determines, in its sole discretion, that the Reverse Stock Split is no longer in the best interests of the Company.

Reverse Stock Split Amendment to the Charter

If the Reverse Stock Split is approved, Article III, Section A of the Charter is amended and restated in its entirety as follows:

“A.Classes of Stock.This Corporation is authorized to issue [●] shares, of which [●] shall be Common Stock with a par value of $0.0001 per share (the “Common Stock”) and [5,000,000] shares shall be Preferred Stock with a par value of $0.0001 per share.

Reverse Stock Split.Effective at 12:01 a.m., Eastern [Daylight Savings] Time on [●] [●], 2016 this Certificate of Amendment of the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Split Effective Time”), the shares of Common Stock issued and outstanding immediately prior to the Split Effective Time and the shares of Common Stock issued and held in the treasury of the Corporation immediately prior to the Split Effective Time are reclassified into a smaller number of shares such that each two to twenty shares of issued Common Stock immediately prior to the Split Effective Time is reclassified into one share of Common Stock, the exact ratio within the two to twenty range to be determined by the board of directors of the Corporation prior to the Split Effective Time and publicly announced by the Corporation. Notwithstanding the immediately preceding sentence, no fractional shares shall be issued and, in lieu thereof, upon surrender after the Split Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Split Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification, following the Split Effective Time, shall be entitled to receive a cash payment equal to the fraction to which such holder would otherwise be entitled multiplied by the closing price of a share of Common Stock on the NASDAQ Capital Market immediately following the Split Effective Time.

Each stock certificate that, immediately prior to the Split Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Split Effective Time shall, from and after the Split Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Split Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Split Effective Time).”

The Certificate of Amendment attached hereto asAnnex Areflects the changes that will be implemented to our Charter if the Reverse Stock Split is approved.

Principal Effects of the Reverse Stock Split

If the stockholders approve the proposal to authorize the Board of Directors to implement the Reverse Stock Split and the Board of Directors implements the Reverse Stock Split, we will amend the existing provision of Article III of our Charter in the manner set forth above.

By approving this amendment, stockholders will approve the combination of any whole number of shares of common stock between and including two (2) and twenty (20), with the exact number to be determined by the Board of Directors, into one (1) share. The Certificate of Amendment to be filed with the Secretary of State of the State of Delaware will include only that number determined by the Board of Directors to be in the best interests of the Company and its stockholders.

9


In accordance with these resolutions, the Board of Directors will not implement any amendment providing for a different split ratio.

As explained above, the Reverse Stock Split will be effected simultaneously for all issued and outstanding shares of common stock and the exchange ratio will be the same for all issued and outstanding shares of common stock. The Reverse Stock Split will affect all of our stockholders uniformly and will not affect any stockholder’s percentage ownership interests in the Company, except to the extent that the Reverse Stock Split results in any of our stockholders receiving a cash payment in lieu of owning a fractional share, as described in the section titled “Fractional Shares,” below. Common stock issued pursuant to the Reverse Stock Split will remain fully paid andnon-assessable. The Reverse Stock Split will not affect the Company’s continuing obligations under the periodic reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Following the Reverse Stock Split, our common stock will continue to be listed on The NASDAQ Capital Market, under the symbol “GALE,” although it would receive a new CUSIP number.

Upon effectiveness of the Reverse Stock Split, the number of authorized shares of common stock that are not issued or outstanding will increase because the proposed amendment will not reduce the number of authorized shares, while it will reduce the number of outstanding shares by a factor of between and including two and twenty, depending on the exchange ratio selected by the Board of Directors.

The shares that are authorized but unissued after the Reverse Stock Split will be available for issuance, and, if we issue these shares, the ownership interest of holders of our common stock will be diluted. We may issue such shares to raise capital and/or as consideration in acquiring other businesses, assets, or establishing strategic relationships with other companies. Such acquisitions or strategic relationships may be effected using shares of common stock or other securities convertible into common stock and/or by using capital that may need to be raised by selling such securities. We do not have any agreement, arrangement or understanding at this time with respect to any specific acquisition for which the newly unissued authorized shares would be issued.

Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates

If the Reverse Stock Split is approved by the Company’s stockholders, and if at such time the Board of Directors still believes that a Reverse Stock Split is in the best interests of the Company and its stockholders, the Board of Directors will determine the ratio of the Reverse Stock Split to be implemented. The Reverse Stock Split will become effective as of 12:01 a.m. Eastern Time on the date specified in the Certificate of Amendment as filed with the office of the Secretary of State of the State of Delaware (the “effective time”). The Board of Directors will determine the exact timing of the filing of the Certificate of Amendment based on its evaluation as to when the filing would be the most advantageous to the Company and its stockholders and publicly announced in a press release. If the Board of Directors does not decide to effect the Reverse Stock Split within twelve months from the date of the Special Meeting, the authority granted in this proposal to effect the Reverse Stock Split will terminate.

Except as described below under the section titled “Fractional Shares,” at the effective time, each whole number of issued and outstandingpre-reverse split shares that the Board of Directors has determined will be combined into onepost-reverse split share, will, automatically and without any further action on the part of our stockholders, be combined into and become one share of common stock, and each certificate which, immediately prior to the effective time representedpre-reverse stock split shares, will be deemed for all corporate purposes to evidence ownership ofpost-reverse split shares.

Fractional Shares

No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders of record at the effective time of the Reverse Stock Split who otherwise would be entitled to receive fractional shares because they hold a number ofpre-split shares not evenly divisible by the number ofpre-split shares for which eachpost-split share is to be exchanged, will, in lieu of a fractional share, be entitled, upon surrender to the exchange agent of certificate(s) representing suchpre-split shares, to a cash payment in lieu thereof. The cash payment will equal the fraction to which the stockholder would otherwise be entitled multiplied by the average of the closing prices (as adjusted to reflect the Reverse Stock Split) of our common stock, as reported by NASDAQ Capital Markets, during the ten consecutive trading days ending on the trading day that is the second day immediately prior to the date on which the Reverse Stock Split becomes effective.

Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, sums due for fractional interests that are not timely claimed after the effective time may be required to be paid to the designated agent for each such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds may have to seek to obtain them directly from the state to which they were paid.

10


Risks Associated with the Reverse Stock Split

We cannot predict whether the Reverse Stock Split will result in an increase in the market price for our common stock over an extended period of time. The history of similar stock split combinations for companies in like circumstances is varied, and the market price of our common stock will also be based on our performance and other factors most of which are unrelated to the number of shares outstanding. Further, there are a number of risks associated with the Reverse Stock Split, including:

The market price per share of our shares of common stockpost-Reverse Stock Split may not remain in excess of the $1.00 minimum bid price per share as required by NASDAQ, or the Company may fail to meet the other requirements for continued listing on NASDAQ, including the minimum value of listed securities, as described above, resulting in the delisting of our common stock.

Although the Board of Directors believes that a higher stock price may help generate the interest of new investors, the Reverse Stock Split may not result in aper-share price that will successfully attract certain types of investors and such resulting share price may not satisfy the investing guidelines of institutional investors or investment funds. Further, other factors, such as our financial results, market conditions and the market perception of our business, may adversely affect the interest of new investors in the shares of our common stock. As a result, the trading liquidity of the shares of our common stock may not improve as a result of the Reverse Stock Split and there can be no assurance that the Reverse Stock Split, if completed, will result in the intended benefits described above.

The Reverse Stock Split could be viewed negatively by the market and other factors, such as those described above, and may adversely affect the market price of the shares of our common stock. Consequently, the market price perpost-Reverse Stock Split shares may not increase in proportion to the reduction of the number of shares of our common stock outstanding before the implementation of the Reverse Stock Split. Accordingly, the total market capitalization of our shares of common stock after the Reverse Stock Split may be lower than the total market capitalization before the Reverse Stock Split. Any reduction in total market capitalization as the result of the Reverse Stock Split may make it more difficult for us to meet the NASDAQ Listing Rule regarding minimum value of listed securities, which could result in our shares of common stock being delisted from The NASDAQ Capital Market.

The Reverse Stock Split may result in some stockholders owning “odd lots” of less than 100 shares of common stock. Odd lot shares may be more difficult to sell, and brokerage commissions and other costs of transactions in odd lots are generally somewhat higher than the costs of transactions in “round lots” of even multiples of 100 shares. Additionally, any reduction in brokerage commissions resulting from the Reverse Stock Split, as discussed above, may be offset, in whole or in part, by increased brokerage commissions required to be paid by stockholders selling odd lots created by the Reverse Stock Split.

Because the Reverse Stock Split will not affect the number of authorized shares of common stock, a Reverse Stock Split will have the effect of increasing the number of authorized but unissued shares of our common stock. The issuance in the future of additional authorized shares will have the effect of diluting the earnings per share and book value per share, as well as the stock ownership and voting rights, of the currently outstanding shares of common stock. In addition, the effective increase in the number of authorized but unissued shares of common stock may be construed as having an anti-takeover effect. Although we are not proposing the Reverse Stock Split for this purpose, we could, subject to the Board of Director’s fiduciary duties and applicable law, issue such additional authorized shares to purchasers who might oppose a hostile takeover bid. Such a use of these additional authorized shares could render more difficult, or discourage, an attempt to acquire control of the Company through a transaction opposed by the Board of Directors.

Additional negative consequences of failing to obtain stockholder approval of either Proposal No. 1 or Proposal No.2 are set forth in the section for Proposal No.2, under the heading “Potential Consequences if Proposal No.1 or Proposal No. 2 are Not Approved.”

Effect on Beneficial Holders of Common Stock (i.e., stockholders who hold in “street name”)

Upon the effectiveness of the Reverse Stock Split, we intend to treat shares of common stock held by stockholders in “street name,” through a bank, broker or other nominee, in the same manner as registered stockholders whose shares of common stock are registered in their names. Banks, brokers or other nominees will be instructed to effect the Reverse Stock Split for their beneficial holders holding the common stock in “street name.” However, these banks, brokers or other nominees may have different procedures than

11


registered stockholders for processing the Reverse Stock Split and making payment for fractional shares. If a stockholder holds shares of common stock with a bank, broker or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker or other nominee.

Beneficial Ownership of Galena’s Common Stock

The following table sets forth information with respect to the beneficial ownership of our common stock as of September 9, 2016, by:

any person known by us to be the beneficial owner of 5% or more of our common stock, including any “group” as that term is defined in the Exchange Act;

each current director and each named executive officer identified in the “Summary Compensation Table” under “Executive Compensation” in the proxy statement filed onWednesday, June 3, 2016 who was still serving in such capacity on September 9, 2016; and19, 2024.

all of our current directors and current executive officers as a group.

Beneficial ownership is determined in accordance with SEC rules, and generally includesWhat am I voting or investment power with respect to securities. Shares of common stock subject to options, warrants and convertible securities that are exercisable or convertible within 60 days are deemed to be outstanding and to be beneficially owned by the person holding the options, warrants or convertible securities for the purpose of computing the percentage ownership of the person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person.

Unless otherwise noted, the information below is based on the number of shares of our common stock beneficially owned by each person or entity at September 9, 2016 and the number of shares subject to any options and warrants granted to these individuals that are exercisable within 60 days of September 9, 2016, which are indicated by footnote. The percentage ownership is based on 214,481,939 shares of common stock outstanding as of September 9, 2016. An asterisk (*) denotes beneficial ownership of less than 1%.

12


   Amount and Nature of Beneficial     
            Name of Beneficial Owner  Ownership       Percentage     

Named Executive Officers and Directors:

    

Mark W. Schwartz, Ph.D.(1)

   1,978,883         *  

John T. Burns (2)

   72,148    

Thomas Knapp (3)

   68,125         *  

Bijan Nejadnik (4)

   105,378    

Richard Chin, M.D.(3)

   237,500         *  

Irving M. Einhorn(3)

   225,000         *  

Stephen S. Galliker(5)

   335,000         *  

Sanford J. Hillsberg(6)

   478,421         *  

William L. Ashton(3)

   225,000         *  

Rudolph Nisi, M.D.(7)

   448,500         *  

Mary Ann Gray, Ph.D. (8)

   164,938         *  
All executive officers and directors as a group — 11 persons(9)   4,338,893     2.02%  

Name and address of 5% Beneficial Owner:

    

 

Sabby Management, LLC(10)

    

 

10 Mountainview Road, Suite 205

   14,000,200     6.53%  

 

Upper Saddle River, New Jersey 07458

    

 

CVI Investments, Inc.(11)

    

 

P.O. Box 309GT

    

 

Ugland House, South Church Street

   14,000,000     6.53%  

 

George Town, Grand Kayman

    

 

KY1-1104, Cayman Islands

    

13


(1)Includes 1,538,905 shares of common stock underlying stock options.
(2)Includes 61,249 shares of common stock underlying stock options.
(3)Consists of shares of common stock underlying stock options.
(4)Includes 96,875 shares of common stock underlying stock options.
(5)Includes 325,000 shares of common stock underlying stock options.
(6)Includes 375,000 shares of common stock underlying stock options.
(7)Includes 425,000 shares of common stock underlying stock options.
(8)Includes 125,000 shares of common stock underlying stock options.
(9)Includes 3,702,654 shares of common stock underlying stock options.
(10)The information shown is based upon a Schedule 13G filed with the SEC on July 12, 2016.
As of the last required reporting date, they met the 5% threshold.
(11)The information shown is based upon a Schedule 13G filed with the SEC on July 15, 2016.
As of the last required reporting date, they met the 5% threshold.

Effect onBook-Entryon? Shares (i.e., stockholders that are registered on the transfer agent’s books and records but do not hold certificates)

If the Reverse Stock Split is effected, stockholders who hold uncertificated shares (i.e., shares held inbook-entry form and not represented by a physical stock certificate), either as direct or beneficial owners, will have their holdings electronically adjusted automatically by our transfer agent (and, for beneficial owners, by their brokers or banks that hold in “street name” for their benefit, as the case may be) to give effect to the Reverse Stock Split. Stockholders who hold uncertificated shares as direct owners will be sent a statement of holding from our transfer agent that indicates the number ofpost-reverse stock split shares of our common stock owned inbook-entry form.

Effect on Certificated Shares

As soon as practicable after the effective time of the Reverse Stock Split, stockholders will be notified that the Reverse Stock Split has been effected. We expect that our transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders ofpre-split shares will be asked to surrender to the exchange agent certificates representingpre-split shares in exchange for certificates representingpost-split shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by us or our exchange agent. No new certificates will be issued to a stockholder until such stockholder has surrendered such stockholder’s outstanding certificate(s) together with the properly completed and executed letter of transmittal to the exchange agent. Anypre-split shares submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged forpost-split shares.STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATE(S) AND SHOULD NOT SUBMIT ANY CERTIFICATE(S) UNTIL REQUESTED TO DO SO.

Principal Effects of Reverse Stock Split on Outstanding Options, Warrants, and Option Plan

As of the Record Date, there were outstanding stock options to purchase an aggregate of 10,554,697 shares of our common stock with a weighted average exercise price of $2.29 per share, and warrants to purchase an aggregate of 37,418,263 shares of common stock with a weighted average exercise price of $1.82 per share. When the Reverse Stock Split becomes effective, the number of shares of common stock covered by such rights will be reduced to between and including one-half and one-twentieth the number currently covered, and the exercise or conversion price per share will be increased by between and including two and twenty times the current exercise or conversion price, resulting in the same aggregate price being required to be paid upon exercise or conversion thereof as was required immediately preceding the Reverse Stock Split.

In addition, the number of shares of common stock and number of shares of common stock subject to stock options or similar rights authorized under the Company’s equity incentive plan and employee stock purchase plan will automatically be proportionately adjusted for the reverse stock split ratio, such that fewer shares will be subject to such plans. Further, the per share exercise price under such plans will automatically be proportionately adjusted for the reverse stock split.

As an example, the following table illustrates the effects of a 1-for-10 Reverse Stock Split, without giving effect to any adjustments for fractional shares of our outstanding common stock, options to purchase our common stock or outstanding warrants to purchase our common stock as of September 9, 2016:

14


   Prior to Reverse
Stock Split
   After 1 for 10 Reverse
Stock Split
 

Common Stock:

    

Outstanding

   214,481,939     21,448,193  

Issuable pursuant to outstanding equity awards

   10,554,697     1,055,469  

Reserved for future issuance under 2016 Incentive Plan

   10,667,630     1,066,763  

Issuable pursuant to outstanding warrants to purchase common stock 

   37,418,263     3,741,826  

Accounting Matters

The Reverse Stock Split will not affect the common stock capital account on our balance sheet. However, because the par value of our common stock will remain unchanged at the effective time of the split, the components that make up the common stock capital account will change by offsetting amounts. Depending on the size of the Reverse Stock Split the Board of Directors decides to implement, the stated capital component will be reduced proportionately based upon the Reverse Stock Split and the additionalpaid-in capital component will be increased with the amount by which the stated capital is reduced. Immediately after the Reverse Stock Split, the per share net income or loss and net book value of our common stock will be increased because there will be fewer shares of common stock outstanding. All historic share and per share amounts in our financial statements and related footnotes will be adjusted accordingly for the Reverse Stock Split.

Effect on Par Value

The proposed amendment to our Charter will not affect the par value of our common stock, which will remain at $0.0001 per share.

No Going Private Transaction

Notwithstanding the decrease in the number of outstanding shares following the proposed Reverse Stock Split, our Board of Directors does not intend for this transaction to be the first step in a “going private transaction” within the meaning of Rule13e-3 of the Exchange Act.

PotentialAnti-Takeover Effect

Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have ananti-takeover effect (for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Board of Directors or contemplating a tender offer or other transaction for the combination of the Company with another company), the Reverse Stock Split proposal is not being proposed in response to any effort of which we are aware to accumulate shares of our common stock or obtain control of the Company, nor is it part of a plan by management to recommend a series of similar amendments to the Board of Directors and stockholders. Other than the Reverse Stock Split proposal, the Board of Directors does not currently contemplate recommending the adoption of any other actions that could be construed to affect the ability of third parties to take over or change control of the Company.

No Dissenters’ Appraisal Rights

Under the Delaware General Corporation Law, the Company’s stockholders are not entitled to dissenters’ appraisal rights with respect to the Reverse Stock Split, and the Company will not independently provide stockholders with any such right.

Material United States Federal Income Tax Consequences of the Reverse Stock Split

The following is not intended as tax or legal advice. Each holder should seek advice based on his, her or its particular circumstances from an independent tax advisor.

The following is a summary of certain United States federal income tax consequences of the Reverse Stock Split generally applicable to beneficial holders of shares of our common stock.

This summary addresses only such stockholders who hold theirpre-reverse stock

15


split shares as capital assets and will hold thepost-reverse stock split shares as capital assets. This discussion does not address all United States federal income tax considerations that may be relevant to particular stockholders in light of their individual circumstances or to stockholders that are subject to special rules, such as financial institutions,tax-exempt organizations, insurance companies, dealers in securities, and foreign stockholders. The following summary is based upon the provisions of the Internal Revenue Code of 1986, as amended, applicable Treasury Regulations thereunder, judicial decisions and current administrative rulings, as of the date hereof, all of which are subject to change, possibly on a retroactive basis. Tax consequences under state, local, foreign, and other laws are not addressed herein. Each stockholder should consult its tax advisor as to the particular facts and circumstances, which may be unique to such stockholder and also as to any estate, gift, state, local or foreign tax considerations arising out of the Reverse Stock Split.

Exchange Pursuant to Reverse Stock Split

No gain or loss will be recognized by a stockholder upon such stockholder’s exchange ofpre-Reverse Stock Split shares forpost-Reverse Stock Split shares pursuant to the Reverse Stock Split, except to the extent of cash, if any, received in lieu of fractional shares, further described in “Cash in Lieu of Fractional Shares” below. The aggregate tax basis of thepost-Reverse Stock Split shares received in the Reverse Stock Split, including any fractional share deemed to have been received, will be equal to the aggregate tax basis of thepre-Reverse Stock Split shares exchanged therefor, and the holding period of thepost-Reverse Stock Split shares will include the holding period of thepre-Reverse Stock Split shares.

Cash in Lieu of Fractional Shares

A holder ofpre-Reverse Stock Split shares that receives cash in lieu of a fractional share ofpost-Reverse Stock Split shares should generally be treated as having received such fractional share pursuant to the Reverse Stock Split and then as having exchanged such fractional share for cash in a redemption by the Company. The amount of any gain or loss should be equal to the difference between the ratable portion of the tax basis of thepre-Reverse Stock Split shares exchanged in the Reverse Stock Split that is allocated to such fractional share and the cash received in lieu thereof. In general, any such gain or loss will constitute a long-term capital gain or loss if the holder’s holding period for suchpre-Reverse Stock Split shares exceeds one year at the time of the Reverse Stock Split. Deductibility of capital losses by holders is subject to limitations.

Interests of Directors and Executive Officers

Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of our common stock.

Reservation of Right to Abandon Reverse Stock Split

We reserve the right to not file the Certificate of Amendment and to abandon any reverse stock split without further action by our stockholders at any time before the effectiveness of the filing with the Secretary of the State of Delaware of the Certificate of Amendment, even if the authority to effect these amendments is approved by our stockholders at the Special Meeting. By voting in favor of Reverse Stock Split, you are expressly also authorizing the Board of Directors to delay, not proceed with, and abandon, these proposed amendments if it should so decide, in its sole discretion, that such action is in the best interests of our stockholders.

Vote Required

The affirmative vote of the holders of a majority of the outstanding shares of our common stock entitled to vote on the matter either in person or by proxy is required to approve the Certificate of Amendment to our Charter to effect the Reverse Stock Split of our common stock. Abstentions and brokernon-votes, if any, will thus count as votes AGAINST the Reverse Stock Split.

Holders of proxies solicited by this Proxy Statement will vote the proxies received by them as directed on the proxy card or, if no direction is made, then FOR the Reverse Stock Split.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE AMENDMENT OF OUR CHARTER TO EFFECT THE REVERSE STOCK SPLIT.

16


Proposal No. 2

Approval of Issuance of Common Stock for Redemption and/or Conversion of Debenture

Reasons for Proposal

In May 2016, we secured a debt financing with JGB (Cayman) Newton Limited (“JGB”) with terms that included a 6.375% original issue discount, a 9% Senior Secured Debenture due November 10, 2018 (as amended, “Debenture”). We amended the Debenture in August 2016 to allow us to repay the Debenture under certain conditions with our common stock and allow the holder of the Debenture to convert some or all of the Debenture into stock under certain conditions. The flexibility to repay this Debenture in either cash or shares of our common stock, together with other financing facilities we have established, provide us with the necessary means to fund our operations. If we decide to pay the Debenture in shares and/or the holder of the Debenture decides to convert the Debenture into our common stock, we may not issue to the holder of the Debenture more than 36,185,586 shares, which represented 19.99% of our outstanding shares of common stock on the date the Debenture was originally issued, without first obtaining stockholder approval. As a result, we are seeking to obtain the requisite stockholder approval to authorize the issuance of shares of our common stock equal to 20% or more of our common stock or 20% or more of our voting power outstanding prior to the sale for less than the greater of book or market value of the stock (the “20% Cap”) to allow us to make the monthly redemptions in shares of our common stock, allow JGB to equitize some or all of the Debenture through a conversion of the outstanding balance of the debt, or allow the issuance of shares upon the exercise by JGB of the warrants.

Our Board of Directors has determined that it is in the best interest of the Company, and in the best interest of our stockholders, to have the ability to issue shares of our common stock in excess of 19.99% of the outstanding shares to allow us to redeem the Debenture by delivering our common stock to the holder of the Debenture and/or the holder to convert the Debenture into our common stock as well as to exercise the warrants whereby reducing the amount of cash necessary to redeem the Debenture over the term of the Debenture.

Our common stock is listed on the NASDAQ Capital Market and we are subject to the NASDAQ Marketplace Rules. NASDAQ Marketplace Rule 5635(d) is commonly referred to as the “NASDAQ 20% Rule.” The NASDAQ 20% Rule requires that a listed company obtain stockholder approval prior to certain issuances of common stock or securities convertible into or exchangeable for common stock at a price less than the greater of market price or book value of common stock. On May 8, 2016, the day before the original issuance date of the Debenture, our common stock had a book value of $0.56 and a market price of $1.25. Because the conversion and redemption prices applicable to the Debenture are or may be less than such amounts, we cannot issue more shares than the 20% Cap unless our stockholders first approve such issuances.

We are seeking stockholder approval to make such issuances of our common stock described above in accordance with Rule 5635 so that we can make as many monthly redemptions of the Debenture with shares of our common stock as we deem appropriate and the Debenture holder can convert some or all of the outstanding balance of the Debenture and obtain shares of our common stock upon the exercise of the Warrants.

As of the record date for the Special Meeting, we have 214,481,939 shares of our common stock issued and outstanding. Based on the current terms of the Debenture and the requirement that the minimum volume-weighted average price of our common stock is not less than $0.20, but disregarding the 20% Cap, we could potentially issue up to a maximum of 138,000,000 shares of our common stock upon redemptions of principal only of the Debenture, which amount would represent 39% of our total outstanding common stock following the issuance of such maximum based on our current outstanding common stock. Accordingly, if this Proposal No. 2 is approved our stockholders may experience significant additional dilution in the event we issue shares of our common stock upon redemptions or conversions of the Debenture in excess of the 20% Cap to which we are currently subject. Such additional dilution would afford our current stockholders a smaller percentage interest in the voting power, liquidation value and aggregate book value of the Company. Additionally, the resale of the shares of our common stock issued in satisfaction of the Debenture into the public markets could cause the market price of our common stock to decline.

Our Board of Directors believes approval of Proposal No. 2 is in the best interests of our Company and our stockholders because it will provide us additional flexibility to determine whether or not to satisfy redemptions and conversions of the Debenture in shares of our common stock or in cash. If Proposal No. 2 is not approved by our stockholders, then we will be limited to issuing a maximum of 36,185,586 shares of our common stock in satisfaction of the Debenture. Any additional payment obligations would need to be satisfied in cash. In order to generate the cash needed to satisfy redemptions of the Debenture, we would likely need to sell shares of our common stock in separate private placements or public offerings, which may be difficult to complete or may need to be completed at times or prices when the market conditions for our common stock are poor. If we are not able to generate the cash needed to satisfy our obligations under the Debenture and do not then have sufficient unrestricted cash to pay redemptions under the Debenture, then we may be forced to default under the Debenture if we have then issued shares up to the 20% Cap. Accordingly, approval of Proposal No. 2 will afford us with significant flexibility to meet our obligations under the Debenture and preserving our cash resources for our planned operating activities.

If Proposal No. 1 is not approved by our stockholders and implemented, approval by our stockholders of this Proposal No. 2 will have no effect as we will not have enough authorized shares to accommodate the monthly redemptions, conversion of the Amended Debenture or exercise of the Warrants, as applicable, and because we would not have obtained the required Stockholder Approval (described above). If Proposal No. 2 is not approved by our stockholders, then we may not issue upon redemption, conversion or otherwise in satisfaction of our obligations under the Debenture more shares than the 20% Cap.

Background; Terms of the Debenture and the Warrants

On May 10, 2016, the Company and JGB (Cayman) Newton Ltd. (the “Purchaser”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company sold and issued to the Purchaser, at a 6.375% original issue discount, a 9% Senior Secured Debenture due November 10, 2018 and having a principal face amount of $25,530,000, and warrants to purchase up to 2,000,000 shares of the Company’s common stock (the “Warrants”). On August 22, 2016, the Company, the Purchaser and certain other parties entered into an Amendment Agreement (the “Amendment Agreement”), which provides for the amendment and restatement of such debenture (as amended, the “Debenture”), an amendment to the terms of the Series A Common Stock Purchase Warrant issued by the Company to the Purchaser pursuant to the terms of the Purchase Agreement, and certain other terms and conditions, as summarized below.

17


Net proceeds to the Company from sale of the Debenture, after payment of commissions and legal fees, were approximately $23,400,000. The Debenture matures November 10, 2018, accrue interest at 9% per year, and does contain a conversion feature into shares of our common stock. The Company intends to use the net proceeds from this offering to fund the costs associated with our GALE-401 clinical trials and other clinical trials of our product candidates, fund any possible future product acquisitions, closing the NeuVax Phase 3 PRESENT study, and to augment its working capital and for general corporate purposes.

The Debenture carries an interest only period of six months to November 2016 following which the Purchaser shall have the rights, at its option, to require the Company to redeem up to $1,500,000 per month of the outstanding principal amount of the Amended Debenture. Interest is payable at the end of each month based on the outstanding principal. During the interest only period, the Company is permitted to satisfy such interest payments in kind by adding such amount to the outstanding principal.

The Company is required to promptly, but in any event no more than three trading days after the Purchaser delivers a redemption notice to the Company, pay the applicable redemption amount in cash or, at the Company’s election and subject to certain conditions, in shares of the Company’s common stock. If the Company elects to pay the redemption amount in shares of its common stock, then the shares will be delivered at the lesser of A) 7.5% discount to the average of the 3 lowest volume weighted average prices over the prior 20 trading days or B) a 7.5% discount to the prior trading day’s volume weighted average price. The Company may only opt for payment in shares of common stock if certain equity conditions are met. The Company, at its option, may also force the Purchaser to redeem up to double the monthly redemption principal amount of the Debenture but not less than the monthly payment. Among the various conditions that must be satisfied in order for the Company to be able to elect to satisfy the monthly redemption amounts in shares of its common stock, the minimum volume-weighted average price of the common stock was decreased from $0.75 to $0.20 per share in the Amended Debenture.

The Purchaser shall continue to have the right under the Debenture, commencing November 10, 2016, to require the Company to redeem the outstanding principal amount in cash, shares of the Company’s common stock or a combination thereof, except that the maximum monthly amount of such redemptions is $1,500,000; provided, that if the trading price of the Company’s common stock is at least $0.40 per share (as adjusted appropriately for stock splits, combinations or similar events) during such calendar month, then such monthly maximum redemption amount may be increased to $2,200,000 at the Purchaser’s election and if the Company has already elected to satisfy such redemptions in shares of common stock. In addition, notwithstanding the foregoing limitations on the monthly redemption amount, the Purchaser may elect up to three times in any 12-month period to increase the monthly maximum to $2,500,000.

The Purchaser can from time to time during the term of the Debenture require the Company to prepay in cash all or a portion of the outstanding principal plus accrued and unpaid interest (the “Outstanding Amount”) on written notice to the Company, provided, that such prepayment amount shall not exceed the lesser of $18,500,000 and the Outstanding Amount. In addition, the Company shall have the right to prepay in cash all (but not less than all) of the Outstanding Amount (1) at any time after November 10, 2017, or (2) upon a “change of control” (as such term is used un the Debenture), in each case with a 10% premium on the Outstanding Amount.

The Debenture provides that, following November 10, 2016, the Purchaser may elect to convert any portion of the Outstanding Amount into shares of common stock at a fixed price of $0.60 per share (as adjusted appropriately for stock splits, combinations or similar events).

Under the Debenture, the Company is required to maintain a minimum of the lesser of $18,500,000 of unencumbered cash or the Outstanding Amount in a restricted account as security for its obligations under the Debenture.

The Company’s obligations under the Debenture can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company’s obligations, the Company would be required to pay all amounts of principal and interest then outstanding under the Amended Debenture in cash. The Company’s obligations under the Debenture are secured under a Security Agreement by a senior lien on all of the Company’s assets, including all of the Company’s interests in its consolidated subsidiaries.

Pursuant to the Purchase Agreement, on May 10, 2016, the Company issued to the Purchaser a Series A Common Stock Purchase Warrant (the “Series A Warrant”) to purchase 1,000,000 shares of the Company’s common stock at a price of $1.51 per share, maturing 5 years from issuance. Additionally, the Purchasers received a Series B Common Stock Purchase Warrant (the “Series B Warrant”) to purchase an additional 1,000,000 shares of common stock on June 29, 2016, the date of the Company’s public announcement of the interim analysis. The Series B Warrant is exercisable at a price of $0.43 per share. In accordance with the terms of the Amendment Agreement, the exercise price of the Series A Warrant was reduced to $0.43 per share (as adjusted appropriately

18


for stock splits, combinations or similar events). If the Purchaser elects such prepayment of the Debenture, then the number of shares subject to the Series A Warrant and Series B Warrant issued to the Purchaser will be reduced in proportion to the percentage of principal required and accrued interest to be prepaid by the Company.

In accordance with the NASDAQ Marketplace Rules, the Debenture continues to provide that the maximum number of shares of common stock that the Company is permitted to issue pursuant to the Amended Debenture is 36,185,586 shares, which amount represented approximately 19.99% of the Company’s outstanding common stock on May 10, 2016. However, the Company has agreed to seek stockholder approval to exceed such limitation in accordance with applicable NASDAQ rules.

A summary of the terms and conditions of the Purchase Agreement, the Debenture, the Warrants, and Amendment Agreement was set forth under Item 5 of Part II of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2016, as filed with the Commission on May 10, 2016 and our Current Report on Form 8-K filed with the SEC on August 23, 2016, which summaries are qualified in their entireties by reference to the full text of the forms of Purchase Agreement, Amended Debenture, Amendment Agreement and Warrants, which are filed as exhibits to such reports. We encourage you to read the Purchase Agreement, Debenture, Amendment Agreement and Warrants and the other related agreements in their entirety.

Potential Consequences if Proposal No. 1 and Proposal No. 2 are Not Approved

The issuance of shares of our common stock upon the monthly redemptions, conversion of the Amended Debenture or exercise of the Warrants is subject to stockholder approval of: (1) either Proposal No.1; and (2) this Proposal No. 2. If these proposals are not approved by our stockholders:

We will be required to redeem our Debenture through payment and delivery of cash which would adversely impact our liquidity;

We may need to raise additional equity capital, in order to pay to the outstanding balance, which may be more costly than utilizing the existing provisions of the Debenture for retirement of the Debenture with issuance of our common stock;

We may not be able to adequately finance our operations, advance our clinical trials of our product assets, expand our pipeline or enter into other strategic transactions.

If we fail to obtain stockholder approval of Proposal No. 2 at the Special Meeting, we intend to continue to seek to obtain stockholder approval at subsequent annual meetings of stockholders and/or special meetings of stockholders until such approval has been obtained and we will incur the costs associated therewith.

Vote Required

The affirmative vote of holders of a majority of our common stock voting at the Special Meeting is required to approve the issuance of shares upon conversion of the Debenture.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” APPROVAL OF ISSUANCE OF COMMON STOCK FOR REDEMPTION AND/OR CONVERSION OF DEBENTURE

19


Proposal No. 3

Adjournment Proposal

If at the Special Meeting the number of shares of common stock present or represented and voting in favor of the Reverse Stock Split is insufficient to approve the Reverse Stock Split, management may move to adjourn, postpone or continue the Special Meeting in order to enable the Board of Directors to continue to solicit additional proxies in favor of the proposed Reverse Stock Split.

In this Adjournment Proposal, we are asking you to authorize the holder of any proxy solicited by the Board of Directors to vote in favor of adjourning, postponing or continuing the Special Meeting and any later adjournments. If the stockholders approve the Adjournment Proposal, we could adjourn, postpone or continue the Special Meeting, and any adjourned session of the Special Meeting, to use the additional time to solicit additional proxies in favor of the Reverse Stock Split. Among other things, approval of the Adjournment Proposal could mean that, even if proxies representing a sufficient number of votes against the Reverse Stock Split have been received, we could adjourn, postpone or continue the Special Meeting without a vote on the Reverse Stock Split and seek to convince the holders of those shares to change their votes to votes in favor of the Reverse Stock Split.

Vote Required

The affirmative vote of holders of a majority of our common stock voting at the Special Meeting is required to approve the Adjournment. Abstentions and brokernon-votes will not be counted as votes cast and, therefore, will have no impact on the approval of this proposal. No proxy that is specifically marked AGAINST the Reverse Stock Split will be voted in favor of the Adjournment Proposal, unless it is specifically marked FOR the discretionary authority to adjourn, postpone or continue the Special Meeting to a later date.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE ADJOURNMENT PROPOSAL.

20


Other Matters

Stockholder Proposals

Any proposal that a stockholder intends to present in accordance with Rule 14a-8 of Exchange Act of 1934 at our annual meeting of Stockholders to be held in 2017 must be received by us on or before February 6, 2017. Only proper proposals under Rule 14a-8, which are timely received, will be included in the proxy statement in 2017.

Additionally, stockholders who intend to present a stockholder proposal at the 2017 annual meeting must provide the Secretary of the Company with written notice of the proposal not fewer than 90 nor more than 120 days prior to the anniversary date of the 2016 annual meeting, provided, however, that if the 2017 annual meeting date is more than 30 days before or after the anniversary date of the 2016 annual meeting, then stockholders must provide notice on or before 10 days after the day on which the date of the 2017 annual meeting is first disclosed in a public announcement. Notice must be tendered in the proper form prescribed by our Bylaws. Proposals not meeting the requirements set forth in our Bylaws will not be entertained at the meeting.

Additionally, any stockholder seeking to recommend a director candidate or any director candidate who wishes to be considered by the Nominating & Governance Committee, the committee that recommends a slate of nominees to the Board of Directors for election at each annual meeting, must provide the Secretary of the Company with a completed and signed biographical questionnaire on or before the Proxy Deadline. Stockholders can obtain a copy of this questionnaire from the Secretary of the Company upon written request. The Nominating & Governance Committee is not required to consider director candidates received after this date or without the required questionnaire. The Nominating & Governance Committee will consider all director candidates who comply with these requirements and will evaluate these candidates using the criteria described above under the caption, “Nomination of Directors.” Director candidates who are then approved by the Board of Directors will be included in the Company’s proxy statement for that annual meeting.

Revocation of Proxy

Subject to the terms and conditions set forth in this proxy statement, all proxies received by us will be effective, notwithstanding any transfer of the shares to which those proxies relate, unless prior to the closing of the polls at the Special Meeting, we receive a written notice of revocation signed by the person who, as of the record date, was the registered holder of those shares. The notice of revocation must indicate the certificate number and numbers of shares to which the revocation relates and the aggregate number of shares represented by the certificate(s). Any stockholder voting by proxy also has the right to revoke the proxy at any time before the polls close at the Special Meeting by giving our corporate secretary a duly executed proxy card bearing a later date than the proxy being revoked at any time before that proxy is voted or by appearing at the meeting and voting in person.

Expenses of Solicitation

We will bear the cost of soliciting proxies in the accompanying form. In addition to the use of the mails, proxies may also be solicited by our directors, officers or other employees, personally or by telephone, facsimile or email, none of whom will be compensated separately for these solicitation activities.

We have also engaged Georgeson, LLC to assist in the solicitation of proxies. We will pay Georgeson a fee of $7,500 plus certain out-of-pocket expenses and flat fees of $6.00 per completed proxy solicitation call and $4.00 per telephone vote.

Delivery of Proxy Materials to Households

Some banks, brokers, and other nominee record holders may be participating in the practice of “householding” proxy statements and annual reports. This means that only one copy of this notice and/or proxy statement may have been sent to multiple stockholders in your household. If you would prefer to receive separate copies of a proxy statement or annual report either now or in the future, please contact your bank, broker or other nominee. Upon written request to us at Galena Biopharma, Inc., Attention: Corporate Secretary, 2000 Crow Canyon Place, Suite 380, San Ramon, California 94583, or by email atinfo@galenabiopharma.com, or by telephone at (855) 855-4253, we will promptly deliver without charge, upon oral or written request, a separate copy of the proxy material to any stockholder residing at an address to which only one copy was mailed. In addition, stockholders sharing an address can request delivery of a single copy of Special reports or proxy statements if they are receiving multiple copies upon written or oral request to us at the physical address, email address, or telephone number stated above.

Miscellaneous

Our management does not intend to present any other items of business and is not aware of any matters other than those set forth in this proxy statement that will be presented for action at the Special Meeting. However, if any other matters properly come before the Special Meeting, the persons named in the enclosed proxy intend to vote the shares of our common stock that they represent in accordance with their best judgment.

21


Questions and Answers

What is a proxy?

A proxy is a legal designation of another person to vote the stock you own. That other person is called a proxy. The written document by which you designate someone as your proxy is also called a proxy, or a proxy card. By completing, signing and returning the accompanying proxy card, you are designating Mark W. Schwartz, Ph.D., our President and Chief Executive Officer, and Thomas J. Knapp, our Interim General Counsel and Corporate Secretary, as your proxies for the Special Meeting and you are authorizing each of Dr. Schwartz and Mr. Knapp to vote your shares at the Special Meeting as you have instructed them on the proxy card. This way, your shares will be voted whether or not you attend the Special Meeting. Even if you plan to attend the Special Meeting, we urge you to return the accompanying proxy card, or vote in one of the other ways described below under “How can I vote my shares without attending the Special Meeting?” so that your vote will be counted if you later decide not to attend the Special Meeting or are unable to attend.

What is a proxy statement?

A proxy statement is a document that we are required by Securities and Exchange Commission, or “ SEC,” regulations to give you when we ask you to designate Dr. Schwartz and Mr. Knapp as your proxies to vote on your behalf.

What is in this proxy statement?

This proxy statement describes the proposals on which we would like you, as a stockholder, to vote at the Special2024 Annual Meeting. It givesThis Proxy Statement provides you with information on the proposals, as well as other information about us, so that you can make an informed decision as to whether orand how to vote your stock.

At the Special2024 Annual Meeting, stockholders will act upon the following proposals referred to in the attached notice of Special Meeting and described in detail in this proxy statement:

three proposals:
1.Proposal 1:To elect two (2) Class II directors to serve on the Company’s Board of Directors for a three-year term expiring in 2027.
Proposal 2:To ratify the appointment by our Audit Committee of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
Proposal 3:To approve, amendment to amended and restated Certificateon a non-binding advisory basis, the compensation of Incorporation to effect a Reverse Stock Split;our named executive officers.

2.To authorize the issuance shares of the Company’s common stock issuable upon the redemption, conversion or other satisfaction of the Company’s obligations under its Amended and Restated 9% Original Issue Discount Senior Secured Debenture due November 10, 2018, without the need for any limitation or cap on issuances as required by and in accordance with NASDAQ Marketplace Rule 5635(d); and

3.To approve an adjournment.

In addition, management will report

How does our Board of Directors recommend that I vote on the proposals?
Our Board of Directors recommends that you vote as follows:

FOR” the election of the nominees for Class II directors to serve on the Company’s Board of Directors for a three-year term expiring in 2027.

FOR” the ratification of the appointment of Moss Adams LLP as our current business operations and respond to appropriate questions from stockholders.

Who is entitled to vote atindependent registered public accounting firm for our fiscal year ending December 31, 2024.


FOR the Special Meeting?

Only stockholders of record at the close of business on September 9, 2016, the record date for the Special Meeting, are entitled to notice of, and to vote at, the Special Meeting or any adjournment or postponement thereof.

What is the difference between holding shares as a stockholder of record and as a beneficial owner?

Mostcompensation of our stockholders hold their shares through a broker, bank or other nominee rather than directlynamed executive officers, as disclosed in their own namethis Proxy Statement.

How many votes do I have?
On each matter to be voted upon, you have one vote for each share of common stock you owned as of the stockholder of record. As summarized below, there are some important distinctions between shares held of record and those owned beneficially.

Stockholder of Record If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A., you are considered the stockholder of record with respect to these shares. As the stockholder of record, you have the right to these shares to grant your voting proxy directly to us or to vote in person at the Special Meeting.

Beneficial Owner If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the beneficial owner of shares held in street name and your broker or nominee is considered the stockholder of record with respect to those shares. As the beneficial owner of these shares, you have the right to direct your broker or nominee on how to vote these shares and are also invited to attend the Special Meeting. However, since you are not the stockholder of record, you may not vote these shares in person at the Special Meeting unless you receive a proxy from your broker or nominee. Your broker or nominee has provided voting instructions for you to use. If you wish to attend the Special Meeting and vote in person shares held in street name, please contact your broker or nominee so that you can receive a proxy to present at the Special Meeting.

22


Record Date.

What does it meanhappens if I receive more than one proxy card?

It means that you have multiple accounts at our transfer agent or with your broker, bank or other nominee. Please complete, sign and return all proxy cards to ensure that all your shares are voted. Unless you need multiple accounts for specific purposes, it may be less confusing if you consolidate as manydo not vote?

Stockholder of your transfer agent or brokerage accounts as possible under the same name and address.

What constitutes a quorum?

Our bylaws provide that the presence,Record: Shares Registered in person or by proxy, at the Special Meeting of the holders of a majority of outstanding shares of our common stock will constitute a quorum for the transaction of business. On the record date, there were 214,481,939 shares of our common stock issued and outstanding, exclusive of treasury shares.

For the purpose of determining the presence of a quorum, proxies marked “withhold authority” or “abstain” will be counted as present. Shares represented by proxies that include so-called broker non-votes, also will be counted as shares present for purposes of establishing a quorum.

What are Abstentions?

An “ABSTENTION” occurs when a stockholder sends in a proxy marked “ABSTAIN” regarding a particular proposal. For purposes of establishing a quorum, shares that the holders abstain from voting in person and shares covered by proxies received but marked “ABSTAIN” as to any or all proposals count as present at the Special Meeting.

As to Proposals No. 1 through No.3, however, regarding the Approval of Amendment to Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split, Authorize the issuance of our common stock in excess of 19,99% of the outstanding shares upon the redemption and/or conversion of 6.375% original issue discount, a 9% Senior Secured Debenture due November 10, 2018 and exercise of the warrants, and Approval of Adjournment, respectively, an abstention will have the same effect as a vote “AGAINST” the proposal.

What are the voting rights of the holders of Galena common stock?

Each share of our common stock entitles the holder to one vote on all matters to come before the Special Meeting. The following voting rights are associated with respect to the proposals:

As to Proposal No. 1 regarding Approval of Amendment to Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split, you may vote “FOR,” “AGAINST,” or “ABSTAIN.”

As to Proposal No. 2 regarding Authorize the issuance shares of the Company’s common stock issuable upon the redemption, conversion or other satisfaction of the Company’s obligations under its Amended and Restated 9% Original Issue Discount Senior Secured Debenture due November 10, 2018, without the need for any limitation or cap on issuances as required by and in accordance with NASDAQ Marketplace Rule 5635(d), you may vote “FOR,” “AGAINST,” or “ABSTAIN.”

As to Proposal No. 3 regarding the Approval of Adjournment, you may vote “FOR,” “AGAINST,” or “ABSTAIN.”

How will my shares be voted if I am a stockholder of record?

Your Name

If you are a stockholder of record and do not vote, via the Internet or telephone or by returning a signed proxy card, your shares will not be voted unless you attendvoted.

4

TABLE OF CONTENTS

Beneficial Owner: Shares Registered in the Special Meeting and vote your shares. If you vote via the InternetName of Broker or telephone and do not specify contrary voting instructions, your shares will be voted in accordance with the recommendations of our Board of Directors. Similarly, if you sign and submit your proxy card or voting instruction card with no instructions, your shares will be voted in accordance with the recommendations of our Board of Directors.

If I am a beneficial owner of shares, can my brokerage firm vote my shares?

Bank

If you are a beneficial owner of shares held in “street name” and you do not provide instructions on how to vote viayour shares, your broker, bank, or other nominee may still be able to vote your shares in its discretion. A broker, bank, or other nominee may generally vote in their discretion on routine matters. In this regard, Proposals 1 and 3 are considered to be “non-routine,” meaning that if your broker, bank, or other nominee does not receive instructions from you on how to vote your shares on such non-routine matter, it will not have the Internet or telephone or by returning a signed voting instruction cardauthority to vote on the matter with respect to your shares. This is generally referred to as a “broker non-vote.” Therefore, broker non-votes may exist in connection with Proposals 1 and 3. However, Proposal 2 is considered to be a “routine” matter, meaning that if you do not return voting instructions to your broker, bank, or other nominee by its deadline, your shares may be voted only with respect to so-called routine matters where your broker has discretionary voting authority over your shares. Brokersby it in its discretion on Proposal 2.
What if I return a proxy card or otherwise vote but do not have such discretionary authority tomake specific choices?
If you return a signed and dated proxy card or otherwise vote on any of the proposals.

We encourage you to provide instructions to your brokerage firm by returning yourwithout marking voting instruction card. This ensures thatselections, your shares will be voted, as applicable:


FOR” the election of two Class II directors to serve on our Board for a three-year term expiring in 2027.

FOR” the ratification of the appointment by our Audit Committee of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

FOR” the advisory approval of named executive compensation.
If any other matter is properly presented at the Special2024 Annual Meeting, your proxyholder will vote your shares using their best judgment.
Who is paying for this proxy solicitation?
We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other nominees for the cost of forwarding proxy materials to beneficial owners. We have engaged Alliance Advisors, LLC to assist in the solicitation of proxies and provide related advice and information support, for a services fee and the reimbursement of customary disbursements, which are not expected to exceed $22,000 in total.
Can I change my vote after submitting my proxy?
Stockholder of Record: Shares Registered in Your Name
Yes. You can revoke your proxy at any time before the final vote at the 2024 Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:

You may submit another properly completed proxy card with a later date.

You may grant a subsequent proxy by telephone or through the Internet.

You may send a timely written notice that you are revoking your proxy to our Corporate Secretary at SELLAS Life Sciences Group, Inc., Times Square Tower, 7 Times Square, Suite 2503, New York, New York 10036.

You may cast a vote online at the meeting.
Your most current proxy card or telephone or Internet proxy is the one that is counted.
Beneficial Owner: Shares Registered in the Name of Broker or Bank
If your shares are held by your broker, bank, or other nominee, you should follow the instructions provided by your broker, bank or other nominee.

5

TABLE OF CONTENTS

How are votes counted?
Votes will be counted by the inspector of election appointed for the 2024 Annual Meeting, who will separately count, with respect to all(i) the proposal to elect directors, votes “For,” “Withhold,” and broker non-votes; and (ii) Proposals 2 and 3, votes “For” and “Against,” abstentions, and, if applicable, broker non-votes.
What are “broker non-votes”?
As discussed above, when a beneficial owner of shares held in “street name” does not give instructions to his or her broker, bank or nominee holding the proposals describedshares as to how to vote on matters deemed to be “non-routine” under NYSE rules, the broker, bank or nominee cannot vote the shares. These unvoted shares are counted as “broker non-votes.” Proposals 1 and 3 are considered to be “non-routine” under NYSE rules and we, therefore, expect broker non-votes to exist in this proxy statement.

23


What happens ifconnection with those proposals.

As a director nominee is unable to stand for election?

Our Board of Directors may reduce the number of nominees or select a substitute nominee. In the latter case,reminder, if you have completed, signed and returned your proxy card, Dr. Schwartz and Mr. Knapp can voteare a beneficial owner of shares held in “street name,” in order to ensure your shares for a substitute nominee. They cannot vote for more than three nominees.

Is my vote kept confidential?

Proxies, ballots andare voted in the way you would prefer, you must provide voting tabulations identifying stockholders are kept confidential and will not be disclosedinstructions to third parties except as may be necessary to meet legal requirements.

What vote is required foryour broker, bank, or other nominee holding the proposals?

The followingshares by the deadline provided in the materials you receive from your broker or bank.

How many votes are required with respectneeded to the proposals:

approve each proposal?
As to Proposal No. 1 regarding Approval of Amendment to Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split the affirmative voteThe holders of a majority of the shares of our common stock issued and outstanding and entitled to vote at the Special2024 Annual Meeting is required.

Aswill constitute a quorum for the transaction of business at the 2024 Annual Meeting. Shares of common stock represented in person or by proxy (including shares which abstain or do not vote with respect to Proposal No.2 regarding Authorize the issuance sharesone or more of the Company’s common stock issuable uponmatters presented for stockholder approval) will be counted for purposes of determining whether a quorum is present at the redemption, conversion or other satisfaction2024 Annual Meeting. The following votes are required for approval of the Company’s obligations under its Amended and Restated 9% Original Issue Discount Senior Secured Debenture due November 10, 2018, withoutproposals being presented at the need for any limitation or cap on issuances as required2024 Annual Meeting:
Proposal 1: To Elect Two Class II Directors.   Directors are elected by and in accordance with NASDAQ Marketplace Rule 5635(d),a plurality of the affirmative votevotes of a majoritythe holders of the shares present in person or represented by proxy and entitled to vote on the election of directors. Accordingly, the two nominees receiving the highest number of affirmative votes will be elected. The nominees for Class II directors to be considered at the Special2024 Annual Meeting are David A. Scheinberg and Katherine Bach Kalin. Shares represented by executed proxies will be voted, if authority to do so is required.not withheld, for the election of the foregoing Class II directors.

AsProposal 2: To Ratify the Appointment by the Audit Committee of Moss Adams LLP as our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024.   A majority of the votes cast is required for the ratification of the appointment of Moss Adams LLP as our independent registered public accounting firm for the current fiscal year.
Proposal 3: To approve, on a non-binding advisory basis, the compensation of our Named Executive Officers.   This proposal calls for a non-binding advisory vote, and accordingly there is no “required vote” that would constitute approval. However, our Board of Directors, including our compensation committee, values the opinion of our stockholders and we will consider our stockholders’ concerns to the extent there are a substantial number of votes cast against the executive officer compensation as disclosed in this Proxy Statement and evaluate what actions may be appropriate to address those concerns.
Shares that abstain from voting as to a particular matter and shares held in “street name” by brokerage firms who indicate on their proxies that they do not have discretionary authority to vote such shares as to a particular matter will not be counted as votes cast on such matter. Accordingly, abstentions and “broker non-votes” will have no effect on the voting on Proposals 1 and 3. Brokerage firms have authority to vote customers’ unvoted shares held by the firms in “street name” on Proposal No. 3 regarding2. If a broker does not exercise this authority, such broker non-votes will have no effect on the Approvalresults of Adjournment,this vote; abstentions will have no effect on the affirmativeresults of Proposal 2.

6

TABLE OF CONTENTS

What is the quorum requirement?
A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of our outstanding shares of the common stock entitled to vote are present at the 2024 Annual Meeting in person or represented by proxy. On the Record Date, there were 57,754,928 shares issued and outstanding and entitled to vote.
Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you cast your vote online. If there is no quorum, the holders of a majority of the shares present in personat the 2024 Annual Meeting or represented by proxy and entitledmay adjourn the 2024 Annual Meeting to vote at the Special Meeting is required.another date.

What are the Board of Directors’ recommendations?

The recommendations of our Board of Directors are set forth together with the description of each proposal in this proxy statement. In summary, our Board of Directors recommends a vote:

FOR” Approval of Amendment to Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split as described in Proposal No.1;

FOR” Authorize the issuance shares of the Company’s common stock issuable upon the redemption, conversion or other satisfaction of the Company’s obligations under its Amended and Restated 9% Original Issue Discount Senior Secured Debenture due November 10, 2018, without the need for any limitation or cap on issuances as required by and in accordance with NASDAQ Marketplace Rule 5635(d), as described in Proposal No.2; and

FOR” Approval of Adjournment as described in Proposal No.3

How can I attendfind out the Special Meeting?

You may attend the Special2024 Annual Meeting if you are listed as a stockholder of record as of September 9, 2016 and bring proof of your identity. If you hold your shares in street name through a broker or other nominee, youvoting results?

Preliminary voting results will need to provide proof that you are the beneficial owner of the shares by bringing either a copy of a brokerage statement showing your share ownership as of September 9, 2016, or a proxy card if you wish to vote your shares in personbe announced at the Special2024 Annual Meeting. In addition, to the items mentioned above, you must bring proof of your identity.

How can I vote my shares in person at the Special Meeting?

Shares held directly in your name as the stockholder of record may be voted in person at the Special Meeting. If you choose to do so, please bring proof of your identity to the Special Meeting. Shares held in street name beneficially owned may be voted by you if you receive and present at the Special Meeting a proxy from your broker or nominee, together with proof of your identity. Even if you plan to attend the Special Meeting, we urge you to vote in one of the ways described below so that your votefinal voting results will be counted if you later decide not to attend the Special Meeting or are unable to attend. Attendance at the Special Meeting will not cause your previously granted proxy to be revoked unless you change your proxy instructions as described above.

How can I vote my shares without attending the Special Meeting?

Whether you hold shares directly as the stockholder of record or beneficially in street name, you may direct your vote without attending the Special Meeting. You may vote by granting a proxy or, for shares held in street name, by submitting voting instructions

24


to your broker or nominee. In most instances, you will be able to do this over the Internet, by telephone or by mail. Please refer to the summary instructions below, the instructions included on the Notice of Internet Availability of the proxy materials, and if you request printed proxy materials, the instructions included on your proxy card or, for shares held in street name, the voting instruction card provided by your broker or nominee.

By Internet If you have Internet access, you may submit your proxy from any location in the world by following the Internet voting instructions on the proxy card or voting instruction card sent to you.

By Telephone You may submit your proxy by following the telephone voting instructions on the Notice of Internet Availability you received or by following the telephone voting instructions on the proxy card or voting instruction card sent to you.

By Mail You may do this by marking, dating and signing your proxy card or, for shares held in street name, the voting instruction card provided to you by your broker or nominee, and mailing it in the enclosed, self-addressed, postage pre paid envelope. No postage is required if mailed in the United States.Please note that you will be mailed a printed proxy card or printed voting instruction card only if you request that such printed materials be sent to you by following the instructions in the Notice of Internet Availability for requesting paper copies of the proxy materials.

Can I change my vote or revoke my proxy?

You may change your proxy instructions at any time prior to the vote at the Special Meeting. For shares held directly as the stockholder of record, you may accomplish this by granting another proxy that is properly signed and bears a later date, by sending a properly signed written notice to our Corporate Secretary or by attending the Special Meeting and voting in person. To revoke a proxy previously submitted by telephone or through the Internet, you may simply vote again at a later date, using the same procedures, in which case your later submitted vote will be recorded and your earlier vote revoked. Attendance at the Special Meeting will not cause your previously granted proxy to be revoked unless you change your proxy instructions as described above. For shares held beneficially by you, you may change your vote by submitting new voting instructions to your broker or nominee. All written notices should be addressed as follows:Galena Biopharma, Inc., 2000 Crow Canyon Place, Suite 380, San Ramon, California 94583, Attention: Corporate Secretary.

Where can I find the voting results of the Special Meeting?

We will announce preliminary voting results at the Special Meeting. We will publish final voting resultspublished in a Current Report on Form 8-K filed with the SECthat we expect to file within four business days following the Special2024 Annual Meeting.

If final voting results are not available to us in time to file a Current Report on Form 8-K within four business days following the 2024 Annual Meeting, we intend to file a Current Report on Form 8-K to publish preliminary results and, within four business days following the final results are known to us, file an additional Current Report on Form 8-K to publish the final results.

What if I amreceive more than one notice or proxy card?
You may receive more than one Notice or proxy card if you hold shares of our common stock in more than one account, which may be in registered form or held in street name. Please vote in the manner described above under “How Do I Vote?” for each account to ensure that all of your shares of our common stock are voted.
How may I obtain an additional copy of the proxy materials if I share an address with another stockholder?
Some brokers or other nominee record holders may be sending you a stockholdersingle Notice or, if applicable, a single set of our proxy materials if multiple stockholders of the Company live in your household. This practice, which has been approved by the SEC, is called “householding.” Once you receive notice from your broker or other nominee record how do I consentholder that it will be “householding” the Notice or if, applicable, our proxy materials, the practice will continue until you are otherwise notified or until you notify them that you no longer want to participate in the practice. Stockholders who participate in householding will continue to have access to and utilize separate proxy voting instructions.
We will promptly deliver a separate copy of our Notice or if applicable, our proxy materials to you if you write to our Corporate Secretary at: SELLAS Life Sciences Group, Inc., Times Square Tower, 7 Times Square, Suite 2503, New York, NY 10036, (646) 200-5278. If you want to receive my Special Meetingyour own Notice or, if applicable, set of our proxy materials electronically?

Stockholdersin the future or, if you share an address with another stockholder and together both of record that choose to vote their shares via the Internet will be asked to choose a delivery preference prior to voting their shares. After entering the access information requested by the electronic voting site, click “Login” and then respond as to whether you would like to receive proxy material via electronic delivery. If you would like to receive futureonly a single Notice or, if applicable, set of proxy materials, electronically, which we urge you to do, clickshould contact your broker or other nominee record holder directly or you may contact us at the applicable button, enter and verify your current emailabove address and then click “Continue.” Stockholders of record with multiple Galena accounts will need to consent to electronic delivery for each account separately.

phone number.

When are otherstockholder proposals and director nominations due for next year’s Special Meeting due?

With respectannual meeting?

Proposals of stockholders intended to proposals notbe presented at next year’s annual meeting of stockholders pursuant to Rule 14a-8 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) must be received by us at our principal offices, Times Square Tower, 7 Times Square, Suite 2503, New York, New York 10036, Attention: Corporate Secretary, no later than December 30, 2024, the date that is 120 days prior to the first anniversary of the date of this Proxy Statement, in order to be included in the proxy statement and proxy card relating to that meeting.

7

TABLE OF CONTENTS

If a stockholder wishes to present a proposal at our 2025 annual meeting, but does not wish to have the proposal considered for inclusion in our proxy statement and proxy card, pursuant to Rule 14a-8 of the Exchange Act,advance notice provision in our bylaws, provide that stockholders who wish to propose other business to be brought before the stockholders at the Special Meetingsuch stockholder must notify our Secretary by agive written notice which notice must be receivedto our Corporate Secretary at our principal executive offices not lessat the address noted above. The Corporate Secretary must receive such notice no earlier than 60 days nor moreFebruary 20, 2025, and no later than 90 daysMarch 22, 2025, provided that if the date of the annual meeting of stockholders is held before June 20, 2025, such notice must instead be received by the Corporate Secretary no earlier than the 120th day prior to the anniversary date of the immediately preceding year’s Special Meeting of stockholders. For the 2017 annual meeting of stockholders wishing to present proposals for consideration under these provisions of our bylaws must submit their proposals so that they are received at our principal executive offices not earlier than April 14, 2017 and not later than May 15, 2017 in order to be considered. In the event that the 2017 annual meeting is not held within thirty (30) days before or after such anniversary date, then such proposal shall have been delivered to or mailed and received by the Secretary not later than the close of business on the 90th day prior to the annual meeting of stockholders or the 10th day following the day on which public disclosure of the date of such annual meeting is first made by us in order for such notice to be timely.

8

TABLE OF CONTENTS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information with respect to the beneficial ownership of our common stock as of April 15, 2024 for (i) the named executive officers named in the Summary Compensation Table on page 22 of this Proxy Statement, (ii) each of our directors and director nominees, (iii) all of our current directors and executive officers as a group and (iv) each stockholder known by us to own beneficially more than 5% of our common stock. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. We deem shares of common stock that may be acquired by an individual or group within 60 days of April 15, 2024 pursuant to the exercise of options or warrants or the vesting of restricted stock units to be outstanding for the purpose of computing the percentage ownership of such individual or group, but those shares are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them based on information provided to us by these stockholders. Percentage of ownership is based on 56,267,670 shares of common stock outstanding April 15, 2024.
Name of Beneficial OwnerNumber
Percentage of
Shares
Beneficially
Owned
5% or Greater Stockholders:
Entities affiliated with Anson Advisors, Inc and Anson Funds
Management LP
4,286,619(1)7.6%
Directors and Executive Officers:
Angelos M. Stergiou, President, Chief Executive Officer and Director
402,415(2)*
Barbara A. Wood, Former Executive Vice President, General Counsel and Corporate Secretary
142,717(3)*
John T. Burns, Senior Vice President, Chief Financial Officer
98,866(4)
Jane Wasman, Chair of the Board
35,855(5)*
David A. Scheinberg, Director
36,037(6)*
Robert L. Van Nostrand, Director
35,855(5)*
John Varian, Director
35,855(5)*
Katherine Bach Kalin, Director
32,900(7)*
All current executive officers and directors as a group (7 persons)677,7831.2
*
Represents beneficial ownership of less than one percent (1%) of the outstanding common stock.
(1)
Represents (i) 2,551,965 shares of our common stock and 791,433 shares of our common stock underlying pre-funded warrants to purchase shares of our common stock, held of record by Anson Investments Master Fund LP and (ii) 719,996 shares of our common stock and 223,225 shares of our common stock underlying pre-funded warrants to purchase shares of our common stock, held of record by Anson East Master Fund LP. The number of shares of common stock beneficially owned excludes shares of common stock issuable pursuant to all or a portion of certain outstanding warrants or prefunded warrants upon exercise thereof, as a result of the triggering of the 4.99% beneficial ownership limitation provision in such securities. Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of Anson Investments Master Fund LP and Anson East Master Fund LP (collectively, “Anson”), hold voting and dispositive power over the securities held by Anson. Tony Moore is the managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc. Mr. Moore Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of these securities, except to the extent of their pecuniary interest therein. The principal business address of Anson is Maple Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KYI-1104, Cayman Islands.
(2)
Represents 56,984 shares of our common stock and options to purchase 345,431 shares of our common stock exercisable within 60 days.

9

TABLE OF CONTENTS

(3)
Represents 27,266 shares of our common stock and options to purchase 115,461 shares of our common stock exercisable within 60 days.
(4)
Represents 25,900 shares of our common stock and options to purchase 72,966 shares of our common stock exercisable within 60 days.
(5)
Represents 4,400 shares of our common stock and options to purchase 31,455 shares of our common stock exercisable within 60 days.
(6)
Represents 4,582 shares of our common stock and options to purchase 31,455 shares of our common stock exercisable within 60 days.
(7)
Represents 4,400 shares of our common stock and options to purchase 28,500 shares of our common stock exercisable within 60 days.

10

TABLE OF CONTENTS

MANAGEMENT AND CORPORATE GOVERNANCE
Board of Directors
Our Bylaws provide that our business shall be managed by or under the direction of our Board of Directors. Our Board of Directors is divided into three classes for purposes of election. One class is elected at each annual meeting of stockholders to serve for a three-year term. The size of our Board of Directors had been set at six members since 2022. The Board is currently classified into three classes as follows: (i) Jane Wasman and Robert Van Nostrand are members of Class I with a term ending at the 2026 annual meeting; (ii) David A. Scheinberg and Katherine Bach Kalin are members of Class II with a term ending at the 2024 annual meeting; and (iii) Angelos M. Stergiou and John Varian are members of Class III with a term ending at the 2025 annual meeting.
Our Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee, has nominated each of David A. Scheinberg and Katherine Bach Kalin for election at the 2024 Annual Meeting as a Class II director for a term of three years to serve until the 2027 annual meeting of stockholders, and until their successors have been elected and qualified.
Set forth below are the names of (i) the persons nominated for election as directors, and (ii) those directors whose terms do not expire this year, their ages, their offices in the Company, if any, their principal occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which such persons hold or have held directorships during the past five years as of April 29, 2024. Additionally, information about the specific experience, qualifications, attributes or skills that led to our Board of Directors’ conclusion at the time of filing of this Proxy Statement that each person listed below should serve as a director is set forth below.
Jane Wasman.   Ms. Wasman has been a director of the Company, Chair of the Board and Chair of the Nominating and Corporate Governance Committee of the Board since December 2017. Ms. Wasman became a member of the Audit Committee in 2019 and previously served as a member of the Compensation Committee. Ms. Wasman was President, International & General Counsel and Corporate Secretary of Acorda Therapeutics, Inc., a publicly traded biopharmaceutical company, from October 2012 until December 2019, managing its international, legal, quality, IP and compliance functions. From January 2012 until October 2012, she was Acorda’s Chief, Strategic Development, General Counsel and Corporate Secretary, and from May 2005 until January 2012, she was Acorda’s Executive Vice President, General Counsel and Corporate Secretary. Before joining Acorda, Ms. Wasman was with Schering-Plough Corporation, a global pharmaceutical company, for over eight years, holding various U.S. and international leadership positions, including Staff Vice President and Associate General Counsel. Ms. Wasman earned a J.D. from Harvard Law School and her undergraduate degree magna cum laude from Princeton University. Ms. Wasman is also a member of the board of directors of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a publicly traded biopharmaceutical company. She previously served on the board of Athersys, Inc. (OTC: ATHX), a publicly traded biopharmaceutical company, Cytovia Therapeutics, a private company, and on the board of NewYorkBIO (including its Executive Committee). The Company believes Ms. Wasman’s significant executive and management experience at publicly traded biopharmaceutical companies qualifies her to serve on our Board.
Angelos M. Stergiou, M.D., Sc.D. h.c.   Dr. Stergiou has served as our President and Chief Executive Officer, and a director, since December 2017. Dr. Stergiou founded, in 2012, our predecessor entity, or Private SELLAS, that completed a business combination with Galena Biopharma on December 29, 2017, and served as the President and Chief Executive Officer and a director since that time, both as Chairman from 2012 to July 2016, and as Vice Chairman from July 2016 to December 2017. In connection therewith, Dr. Stergiou led the negotiation of an exclusive license agreement with Memorial Sloan Kettering Cancer Center (“MSK”) to develop and commercialize MSK’s WT1 peptide vaccine technology, which was satisfied in part by the transfer to MSK of certain of Dr. Stergiou’s shares in Private SELLAS. Dr. Stergiou also co-founded Genesis Life Sciences, Ltd. (now Genesis Research), a boutique health economics and pricing-reimbursement and health access company where he served as President and Chief Operating Officer from 2009 to 2011. From 2004 to 2008, Dr. Stergiou served as Vice President and Head of Drug Development at Accentia Biopharmaceuticals, Inc. and also served in the same capacity as well as Chief Medical Officer at its subsidiary Biovest International, Inc. during the same time. While at Biovest International, Inc.,

11

TABLE OF CONTENTS

Dr. Stergiou led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, which was presented at the American Society of Clinical Oncology plenary session in 2009. Dr. Stergiou started his biotechnology career in 2002 at PAION AG where he served as its U.S. program lead of desmoteplase (DEDAS) and served on the joint steering and oversight committee of PAION AG with Forest Laboratories, Inc. in 2003-2004. Dr. Stergiou holds an M.D. from the U.S. American Institute of Medicine and a Sc.D. h.c. from Kentucky Wesleyan College and received his undergraduate degree in pre-medicine, biology and chemistry from Kentucky Wesleyan College. Dr. Stergiou was a member of the Board of Trustees at Kentucky Wesleyan College from March 2017 to January 2021, and is a Fellow of the Royal Society of Medicine, an active member of the World Medical Association, and a member of the American Academy of Physicians in Clinical Research and the Association of Clinical Research Professionals. Dr. Stergiou has served on the Board of Directors of Cleara Biotech B.V., a private biotech company located in the Netherlands, since January 2022. The Company believes that Dr. Stergiou’s experience as the founder of Private SELLAS and as President, Chief Executive Officer and Director of the Company, as well as his extensive experience in the biopharmaceutical industry and his significant management experience, qualifies him to serve on our Board.
David A. Scheinberg, M.D., Ph.D.   Dr. Scheinberg has been a director of the Company and Chair of the Science Committee since December 2017. Dr. Scheinberg is currently the Vincent Astor Chair and Chairman of the Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center (MSK), where he spearheaded the discovery and early clinical development of galinpepimut-S and is the Deputy Director of the Sloan Kettering Institute for Therapeutic Discovery. Additionally, Dr. Scheinberg is a Professor of Medicine and Pharmacology and until 2022, was co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College. He is a Professor in the Gerstner-Sloan Kettering Graduate School at MSK. Dr. Scheinberg is also an attending physician in the Department of Medicine, on the Leukemia Service, which he led as Chief from 1992 -2001. Dr. Scheinberg is an advisor to charitable foundations and cancer centers and sat on the board of directors of Progenics Pharmaceuticals, Inc., a biotechnology company, from 1996 to 2019, which then merged with Lantheus (NASDAQ: LNTH), and currently sits on the board of directors of Sapience Therapeutics, Inc., a privately held, clinical stage biotechnology company. Dr. Scheinberg also served on Private SELLAS’ Scientific Advisory Board from 2015 to 2017. From 2010 through 2016, he served on the board of directors of Contrafect Corporation, a publicly traded clinical-stage biotechnology company. Dr. Scheinberg holds an M.D. and a Ph.D. in Pharmacology and Experimental Therapeutics from the Johns Hopkins University School of Medicine. Dr. Scheinberg earned his undergraduate degree in Biology from Cornell University. The Company believes Dr. Scheinberg’s experience on Private SELLAS’ Scientific Advisory Board and other public board experience, as well as his expertise as a leading academic oncologist and drug developer at MSK, including broad knowledge of and contacts in the highest levels of medical research, qualifies him to serve on our Board.
Robert L. Van Nostrand.   Mr. Van Nostrand has been a director of the Company since December 2017. He was Chair of the Compensation Committee from December 2017 to June 2023. In June 2023, Mr. Van Nostrand became Chair of the Audit Committee. He was a member of the board of directors of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), a biotechnology company, until it was acquired in January 2020. He is a member of the board of directors of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company, Yield10 Bioscience, Inc. (NASDAQ: YTEN), formerly Metabolix, Inc., a bio-agricultural company, Likeminds, Inc., a private biotech company, and the Biomedical Research Alliance of New York, a private company providing clinical trial services. Mr. Van Nostrand was Executive Vice President and Chief Financial Officer of Aureon Laboratories, Inc., a pathology life science company, from January 2010 to July 2010. Prior to joining Aureon Laboratories, Mr. Van Nostrand served as Executive Vice President and Chief Financial Officer of AGI Dermatics, a private biotechnology company, from July 2007 to September 2008, when the company was acquired. Between 1986 and 2007, Mr. Van Nostrand held various executive and other management positions, including Chief Compliance Officer and Chief Financial Officer, at OSI Pharmaceuticals, Inc. (“OSI”). Prior to joining OSI, Mr. Van Nostrand served in a managerial position with the accounting firm, Touche Ross & Co., currently Deloitte. He is a treasurer and member of the board of NewYorkBIO. Mr. Van Nostrand holds a B.S. in Accounting from Long Island University, New York and completed advanced management studies at the Wharton School of the University of Pennsylvania. He was a Certified Public Accountant. The Company believes Mr. Van

12

TABLE OF CONTENTS

Nostrand’s vast board and industry experience in life sciences, his qualification as a financial expert, as well as his experience in transaction structuring and risk management qualifies him to serve on our Board.
John Varian.   Mr. Varian has been a director of the Company since December 2017. He was the Chair of the Audit Committee from December 2017 to June 2023 and remains a member of the Audit Committee. He has been Chair of the Compensation Committee since June 2023. Mr. Varian served as Chief Executive Officer of XOMA Corporation from August 2011 through December 2016 and served as a member of the board of directors of XOMA from December 2008 through May 2017. Mr. Varian served as a member of the board of directors of Versartis, Inc. (NASDAQ: VSAR) from March 2014 through October 2018, when it acquired Aravive, and the board of directors of Egalet Corporation (NASDAQ: EGLT) from June 2018 through February 2019, when it acquired the assets of Iroko. Mr. Varian has also been a member of the board of directors of Acorda Therapeutics, Inc. (NASDAQ: ACOR) since January 2022 and AmMax Bio, Inc. (a privately held clinical stage biotechnology company) since February 2021. Mr. Varian previously served as Chief Operating Officer of ARYx Therapeutics, Inc. from December 2003 through August 2011. Beginning in May 2000, Mr. Varian was Chief Financial Officer of Genset S.A. in France, where he was a key member of the team negotiating Genset’s sale to Serono S.A. in 2002. From 1998 to 2000, Mr. Varian served as Senior Vice President, Finance and Administration of Elan Pharmaceuticals, Inc., joining the company as part of its acquisition of Neurex Corporation. Prior to the acquisition, he served as Neurex Corporation’s Chief Financial Officer from 1997 until 1998. From 1991 until 1997, Mr. Varian served as the VP Finance and Chief Financial Officer of Anergen Inc. Mr. Varian was an Audit Principal/Senior Manager at Ernst & Young LLP from 1987 until 1991, where he focused on life sciences. Mr. Varian was also a founding committee member of Bay Bio and a former chairman of the Association of Bioscience Financial Officers International Conference. Mr. Varian holds a BBA. from Western Michigan University. He was a Certified Public Accountant. The Company believes Mr. Varian’s significant experience working with biopharmaceutical companies, including developing and implementing strategy, with a focus on financing, corporate financial management and related matters, qualifies him to serve on our Board.
Katherine Bach Kalin.   Ms. Kalin has been a director of the Company since August 2022. She has been a member of the Compensation Committee and the Nominating and Corporate Governance Committee since October 2022. Ms. Kalin currently serves as a non-executive director on the boards of Genfit S.A. (NASDAQ: GNFT), a French, public biopharmaceutical company, where she serves on the Strategy and Alliances Committee, and two private companies, Brown Advisory LLC, an independent investment and strategic advisory firm (Audit & Finance Committees), and FemHealth Ventures, a venture capital firm that seeks to invest in women’s health. She was a member of the board of directors of Athersys, Inc. (OTC: ATHX), a biotech focused on regenerative medicine from 2020 to 2022 (Audit and Compensation Committees) and Clinical Genomics, a private, biotech company dedicated to improving patient outcomes through early detection of colorectal cancer (Audit and Financial Risk Committee) from 2018 to 2021. She currently serves as a trustee for a not-for-profit organization, the Summit Foundation, a 501(c)(3) community foundation that fosters local philanthropy. Ms. Kalin has more than 25 years of experience in healthcare and professional services, most recently at Celgene, where she led Corporate Strategy from 2012 to 2017, and at Johnson & Johnson, where she held executive leadership roles in marketing, sales and new business development from 2002 to 2011. Prior to that, Ms. Kalin was a partner in the global healthcare practice at McKinsey & Co., from 1990 to 2002. Her healthcare industry experience spans pharmaceuticals, diagnostics, medical devices, and digital health. Earlier in her career, she served as a Manager in Corporate Finance at Nomura International in the U.K. and Japan from 1980 to 1984. She has a B.A. from Durham University, U.K. and an M.B.A. from Harvard Business School. The Company believes Ms. Kalin’s healthcare industry experience, business strategy, and marketing expertise as well as her past and present experience on the board of other publicly traded companies, qualifies her to serve on our Board.
Independence of the Board of Directors
As required under Nasdaq listing standards, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the board of directors of such listed company. Our Board consults with our internal and outside counsel to ensure that its determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.

13

TABLE OF CONTENTS

Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and us, our senior management and our independent auditors, our Board has affirmatively determined that the following directors are independent directors within the meaning of the applicable Nasdaq listing standards: Jane Wasman, Robert L. Van Nostrand, each Class I directors, David A. Scheinberg, M.D., Ph.D. and Katherine Bach Kalin, each Class II directors, and John Varian, a Class III director. In making this determination, our Board found that none of these directors had a material or other disqualifying relationship with the Company. Dr. Stergiou, who is a Class III director, is an employee and is therefore not “independent.”
Board Leadership Structure
Our Board has an independent Chair, Jane Wasman, who has served as Chair since 2017, and has authority, among other things, to preside over Board meetings and stockholder meetings, and shall have such powers and duties as may from time to time be assigned by the Board. Accordingly, the Chair has substantial ability to shape the work of the Board. We believe that separation of the positions of Chair and Chief Executive Officer reinforces the independence of the Board in its oversight of our business and affairs. In addition, we believe that having an independent Chair creates an environment that is more conducive to objective evaluation and oversight of management’s performance, increasing management accountability and improving the ability of our Board to monitor whether management’s actions are in our best interests and those of our stockholders. As a result, we believe that having an independent Chair can enhance the effectiveness of our Board as a whole. In addition, we have a separate chair for each committee of our Board. The chairs of each committee report to our Board at each quarterly Board meeting on the activities of their committees in fulfilling the responsibilities as detailed in the respective charters or advise of any shortcomings should that be the case.
Role of the Board in Risk Oversight
One of the Board’s key functions is informed oversight of our risk management process. Our Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through the standing committees that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for us. Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our Audit Committee also monitors compliance with certain legal and regulatory requirements, including requirements related to privacy and data protection, and oversees the performance of the internal audit function. Our Nominating and Corporate Governance Committee monitors the effectiveness of our corporate governance guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking.
Management periodically reports to the Board or relevant committee, which provides guidance on risk assessment and mitigation. Each committee charged with risk oversight reports to the Board on risk matters.
Corporate Governance Guidelines
We have adopted Corporate Governance Guidelines to assure that the Board has the necessary authority and practices in place to review and evaluate our business operations as needed and to make decisions that are independent of our management. The guidelines are also intended to align the interests of directors and management with those of our stockholders. The Corporate Governance Guidelines set forth the practices the Board follows with respect to board composition and selection, board meetings and involvement of senior management, Chief Executive Officer performance evaluation and succession planning, and board committees and compensation. The Corporate Governance Guidelines, as well as the charters for each committee of the Board, may be viewed at
https://ir.sellaslifesciences.com/corporate-governance/default.aspx.

14

TABLE OF CONTENTS

Clawback Policy
In March 2021, our Board adopted a clawback policy. The clawback policy applies to all incentive-based compensation granted after the policy’s adoption, including cash and equity incentive awards. The policy provides that if both (1) an accounting restatement is required due to our material noncompliance with any financial reporting requirement under the U.S. federal securities laws and (2) our Board (or a committee thereof), in its sole discretion, determines that an act or omission of a current or former executive officer contributed to the circumstances requiring the restatement and that such act or omission involved fraud or intentional misconduct then we will use reasonable efforts to recover from such person up to 100% of any incentive-based compensation awarded during the three-year period preceding the date on which the noticewe are required to prepare such accounting restatement. In light of the adoption by the SEC in October 2022 of new Rule 10D-1 under the Exchange Act implementing Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we amended and restated our clawback policy, effective September 12, 2023, in accordance with updated Nasdaq listing standards.
Committees of the Board of Directors and Meeting Attendance
Board of Directors.   During the fiscal year ended December 31, 2023, our Board met six times and took action by written consent five times. During 2023, each of our directors attended 100% of the regular meetings of the Board and committees on which he or she then served. Our Board of Directors makes every effort to but is not required to attend each annual meeting of our stockholders. All then-serving directors attended our annual meeting of stockholders held in 2023.
Committees of the Board of Directors.   Our Board has three standing committees: an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. Our Board has determined that each member of these committees meets the applicable Nasdaq rules and regulations regarding “independence” and each member is free of any relationship that would impair his or her individual exercise of independent judgment regarding the Company. Our Board also has a Science Committee, which is a standing committee that meets to review the Company’s clinical programs.
NameAgePosition
Term
Expires
Audit
Committee
Compensation
Committee
Nominating
and
Corporate
Governance
Committee
Science
Committee
Jane Wasman67Chair of the Board2026*
Angelos M. Stergiou48Director, President and
Chief Executive
Officer
2025
David A. Scheinberg68Director2024*
Robert L. Van Nostrand67Director2026*
John Varian64Director2025*
Katherine Bach Kalin61Director2024
*
Denotes Chair of Committee
Audit Committee
The Audit Committee is currently comprised of three directors: Messrs. Varian, Van Nostrand, as chair, and Ms. Wasman. The Audit Committee met four times in 2023. Our Board has adopted a written Audit Committee charter that is available to stockholders in the corporate governance section of our website at: https://ir.sellaslifesciences.com/corporate-governance/default.aspx.
The Audit Committee was mailedestablished by our Board in accordance with Section 3(a)(58)(A) of the Exchange Act to oversee our corporate accounting and financial reporting processes and audits of our financial statements. The Audit Committee’s responsibilities include, among other things:

15

TABLE OF CONTENTS


appointing our independent registered public accounting firm;

evaluating the qualifications, independence and performance of our independent registered public accountants;

reviewing and approving the audit and non-audit services to be performed by the independent registered public accountants and the compensation therefor;

reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our critical accounting policies;

reviewing the design, implementation, adequacy and effectiveness of our internal controls regarding privacy and data protection and our related policies;

conferring with management and the independent registered public accountants regarding the effectiveness of internal control over financial reporting;

discussing with management and the independent registered public accounting firm the results of our annual audit and the review of our quarterly unaudited financial statements;

reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to financial statements or accounting matters;

reviewing and approving transactions between the Company and any related persons;

providing oversight of the Company’s cybersecurity risk management, strategy, and governance; and

reviewing and evaluating, at least annually, the performance of the Audit Committee and its members including compliance of the Audit Committee with its charter.
Our Board reviews the Nasdaq listing standards’ definition of “independence” for Audit Committee members on an annual basis and has determined that all members of our Audit Committee are independent (as currently defined in Rule 5605(c)(2)(A)(i) and (ii) of the Nasdaq listing standards and under Rule 10A-3 under the Exchange Act).
Our Board has also determined that Messrs. Varian and Van Nostrand each qualify as an “audit committee financial expert,” as defined in applicable SEC rules. Our Board made a qualitative assessment of the level of knowledge and experience of both Mr. Varian and Mr. Van Nostrand based on a number of factors, including the formal education and experience of each of Messrs. Van Nostrand and Varian as former chief financial officers for public reporting companies, and the status of Messrs. Van Nostrand and Varian as former Certified Public Accountants.
On March 19, 2024, we amended the charter of the Audit Committee to include the provision of oversight of the Company’s cybersecurity strategy, policies, and other initiatives.
Compensation Committee
The Compensation Committee is currently comprised of three directors: Dr. Scheinberg, Mr. Varian, as chair, and Ms. Kalin. Each of Mr. Varian, Dr. Scheinberg and Ms. Kalin are independent (as independence is currently defined in Rule 5605(d)(2) of the Nasdaq listing standards). Mr. Varian was appointed to the Compensation Committee effective June 20, 2023. The Compensation Committee met four times in 2023 and took action by written consent one time in 2023. Our Board has adopted a written Compensation Committee charter that is available to stockholders in the corporate governance section of our website at: https://ir.sellaslifesciences.com/corporate-governance/default.aspx.
The Compensation Committee acts on behalf of the Board to review, recommend for adoption and oversee our compensation strategy, policies, plans and programs, including:

reviewing and recommending to the full Board for approval corporate performance goals and objectives relevant to the compensation of our executive officers, directors and other senior management and evaluation of performance in light of these stated goals and objectives;

16

TABLE OF CONTENTS


reviewing and recommending to the Board for approval of the compensation and other terms of employment or service, including severance and change-in-control arrangements, of our Chief Executive Officer and the other executive officers and directors;

reviewing and approving (or if it deems it appropriate, making recommendations to the full Board of Directors regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs;

evaluating risks associated with our compensation policies and practices and assessing whether risks arising from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us;

reviewing and making recommendations to the full Board of Directors regarding the type and amount of compensation to be paid or awarded to our non-employee Board members;

establishing policies with respect to votes by our stockholders to approve executive compensation as required by Section 14A of the Exchange Act and determining our recommendations regarding the frequency of advisory votes on executive compensation, to the extent required by law;

reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by Section 10C of the Exchange Act;

administering our equity incentive plans;

establishing policies with respect to equity compensation arrangements;

reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our compensation policy and strategy in achieving expected benefits to us; and

reviewing and assessing on an annual basis the performance of the Compensation Committee and the Compensation Committee charter.
Each year, our Compensation Committee reviews with management our executive compensation tables and accompanying narrative disclosure and considers whether to recommend that it be included in proxy statements and other filings.
Compensation Committee Processes and Procedures
Typically, the Compensation Committee meets three times a year and with greater frequency if necessary. The agenda for each meeting is usually developed by the Chair of the Compensation Committee, in consultation with the Chief Executive Officer. The Compensation Committee meets regularly in executive session. From time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of our Compensation Committee regarding his compensation or individual performance objectives. The charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under the charter, the Compensation Committee has the authority to obtain, at the expense of the Company, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising our Compensation Committee. In particular, the Compensation Committee has the authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant’s reasonable fees. Under the charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Compensation Committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser’s independence; however, there is no requirement that any adviser be independent.

17

TABLE OF CONTENTS

The Compensation Committee has engaged Radford, a division of Aon Hewitt, which is a subsidiary of Aon plc, as its compensation consultant, to evaluate long and short-term executive compensation, director compensation and executive severance plans. The Compensation Committee has assessed the independence of Radford pursuant to SEC rules and has concluded that Radford’s work for the Compensation Committee does not raise any conflict of interest. On an annual basis, Radford reviews our executive officer and director compensation relative to a peer group and against survey data available to Radford. Working with Radford, the Compensation Committee reviews and adjusts our peer group in the latter part of each year for upcoming end-of-year compensation decisions. Decisions regarding 2023 salaries and short-term non-equity incentive plan compensation were made by our Compensation Committee in early 2023 by reference to the peer group determined by our Compensation Committee in late 2022. In establishing the peer group of companies to be used for purposes of setting 2023 executive compensation, the Compensation Committee and Radford, using industry standard parameters for establishing a peer group, sought to identify companies that fit the following criteria:

Publicly-traded, pre-commercial biopharma companies, with a focus on oncology;

Phase 2 or Phase 3 stage of clinical development;

Market capitalization below $500 million; and

fewer than 50 employees.
Based on these criteria, the Compensation Committee identified the following companies for our 2023 peer group: Actinium Pharmaceuticals, Inc., Cardiff Oncology, Checkpoint Therapeutics, Inc., Cidara Therapeutics, Inc., ContraFect Corporation, Corvus Pharmaceuticals, Inc., Cue Biopharma, Inc., Cyclacel Pharmaceuticals, Inc., Elevation Oncology, Inc., Equillium, Inc., Galera Therapeutics, Inc., GlycoMimetics, Inc., Immunic, Inc., Leap Therapeutics, Inc., MEI Pharma, Inc., Oncternal Therapeutics, Inc., PDS Biotechnology Corporation, Selecta Biosciences Inc., Verastem, Inc., and Vincerx Pharma, Inc.
Radford ultimately developed recommendations that were presented to the Compensation Committee for its consideration. Based on these recommendations, we determined our current compensation levels for our executive officers, including base salary and target bonus payments.
Nominating and Corporate Governance Committee
The Nominating and Corporate Governance Committee is responsible for identifying, reviewing and evaluating candidates to serve as directors of the Company (consistent with criteria approved by the Board), reviewing and evaluating incumbent directors, selecting candidates for election to our Board, making recommendations to our Board regarding the membership of the committees of the Board, and assessing the performance of management and our Board.
The Nominating and Corporate Governance Committee is currently comprised of three directors: Ms. Wasman, as chair, Ms. Kalin, and Mr. Van Nostrand. Mr. Varian served on the Nominating and Corporate Governance Committee until June 20, 2023. All members of our Nominating and Corporate Governance Committee are independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards). The Nominating and Corporate Governance Committee met four times in 2023. Our Board has adopted a written Nominating and Corporate Governance Committee charter that is available to stockholders in the corporate governance section of our website at: https://ir.sellaslifesciences.com/corporate-governance/default.aspx. The functions of this committee include, among other things:

identifying, reviewing and evaluating candidates to serve on our Board of Directors consistent with criteria approved by our Board;

evaluating director performance on the Board and applicable committees of the Board and determining whether continued service on our Board is appropriate;

evaluating, nominating and recommending individuals for membership on our Board;

evaluating nominations by stockholders of candidates for election to our Board;

considering and assessing the independence of members of our Board;

18

TABLE OF CONTENTS


developing a set of corporate governance principles, periodically reviewing and assessing these principles and their application and recommending to our Board any changes to such public disclosure was made, whichever occurs first. Proposalspolicies and principles;

considering questions of possible conflicts of interest of directors as such questions arise; and

reviewing and assessing on an annual basis the performance of the Nominating and Corporate Governance Committee and the Nominating and Corporate Governance Committee charter.
On March 2, 2023, we amended the charter of the Nominating and Corporate Governance Committee to include the provision of oversight of the Company’s environmental, social and governance (ESG) strategy, policies and initiatives.
Our Nominating and Corporate Governance Committee believes that it is in the best position to identify, review, evaluate and select qualified candidates for Board membership, based on the comprehensive criteria for Board membership approved by the Board. Generally, our Nominating and Corporate Governance Committee will consider candidates recommended from several sources, such as other directors or officers, stockholders, third party search firms or other appropriate sources. Once identified, the Nominating and Corporate Governance Committee will evaluate a candidate’s qualifications. The Nominating and Corporate Governance Committee believes that candidates for director should have certain qualifications, including the ability to read and understand basic financial statements and the possession of the highest personal integrity and ethics. Candidates for director should also be over 21 years of age. Our Nominating and Corporate Governance Committee also considers such factors as possessing relevant expertise enabling the candidate to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of our stockholders. However, our Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, our Nominating and Corporate Governance Committee typically considers age, skills and such other factors as it deems appropriate, given our current needs and the needs of our Board, to maintain a balance of knowledge, experience and capability and considers issues of diversity among its members in identifying and considering nominees for director, striving where appropriate to achieve a diverse balance of backgrounds, perspectives, experience, age, gender, ethnicity and country of citizenship on our Board of Directors and its committees. Our Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary.
In the case of incumbent directors whose terms of office are set to expire, our Nominating and Corporate Governance Committee reviews these directors’ overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors’ independence. The Committee also takes into account the results of the Board’s self-evaluation, conducted annually on a group and individual basis.
Although the Nominating and Corporate Governance Committee does not have a formal policy with regard to the consideration of director candidates recommended by stockholders, it has the power and authority to consider recommendations for Board nominees and proposals submitted by the Company’s stockholders.
If a stockholder wishes to propose a candidate for consideration as a nominee for election to our Board of Directors, that stockholder must follow the procedures described in our Bylaws. Any such recommendation should be sentmade in writing on a timely basis as set forth in our Bylaws toGalena Biopharma, our Corporate Secretary at our principal office and should be accompanied by the following information concerning the proposed nominee:

all information relating to such person that would be required to be disclosed in a proxy statement;

certain biographical information about the proposed nominee;

19

TABLE OF CONTENTS


the class and number of shares of each class of capital stock of the corporation which are owned of record and beneficially by such proposed nominee; and

the date or dates on which such shares were acquired and the investment intent of such acquisition.
The Company may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as an independent director of the Company or that could be material to a reasonable stockholder’s understanding of the independence, or lack thereof, of such proposed nominee.
Science Committee
The Board has a Science Committee that meets at least quarterly to review the Company’s clinical programs and is currently comprised of Dr. David A. Scheinberg, as Chair, and Dr. Angelos M. Stergiou and Mr. John Varian, as members. The Science Committee met four times in 2023.
Report of the Audit Committee of the Board of Directors
The Audit Committee of the Board of Directors of SELLAS Life Sciences Group, Inc. consists of three members, each of whom the Board has determined meets the independence and experience requirements of the Nasdaq Capital Market and includes two “audit committee financial experts” within the meaning of the U.S. Securities and Exchange Commission’s rules.
In fulfilling its responsibilities for the financial statements for fiscal year December 31, 2023, the Audit Committee took the following actions:

Reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2023 with management and Moss Adams LLP, our independent registered public accounting firm;

Discussed with Moss Adams LLP the matters required to be discussed in accordance with Auditing Standard No. 1301- Communications with Audit committees; and

Received written disclosures and the letter from Moss Adams LLP regarding its independence as required by applicable requirements of the Public Company Accounting Oversight Board regarding Moss Adams LLP’s communications with the Audit Committee and the Audit Committee further discussed with Moss Adams LLP their independence. The Audit Committee also considered taxation matters and other areas of oversight relating to the financial reporting and audit process that the committee determined appropriate.
Based on the Audit Committee’s review of the audited financial statements and discussions with management and Moss Adams LLP, the Audit Committee recommended to our Board, and the Board approved, that the audited financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 for filing with the SEC.
Members of the Company’s Audit Committee: Messrs. Robert L. Van Nostrand and John Varian, and Ms. Jane Wasman.
Policy Prohibiting Pledges
Our Insider Trading Policy provides that no employee, officer or director may purchase Company securities on margin, borrow against Company securities held in a margin account, or pledge Company securities as collateral for a loan. However, an exception may be granted where a person wishes to pledge Company securities as collateral for a loan and clearly demonstrates the financial capacity to repay the loan without resorting to the pledged securities.
Stockholder Communications with the Board of Directors
The Board expects that the views of our stockholders pertinent to matters relating to our business will be heard by the Board, its committees, or individual directors, as applicable, and that appropriate responses be provided to stockholders on a timely basis. Stockholders wishing to formally communicate with the

20

TABLE OF CONTENTS

Board, any committee of the Board, the independent directors as a group or any individual director may send communications directly to us at SELLAS Life Sciences Group, Inc., 2000 Crow Canyon Place,Times Square Tower, 7 Times Square, Suite 380, San Ramon, California 94583,2503, New York, New York 10036, Attention: Corporate Secretary. A stockholder’s notice All clearly marked written communications, other than unsolicited advertising or promotional materials, are logged and copied, and forwarded, as may be warranted, to bringthe director(s) to whom the communication was addressed. Undirected communications will be distributed to our entire Board, or to any individual director or directors as appropriate, depending on the facts and circumstances outlined in the communications. Please note that the foregoing communication procedure does not apply to (i) stockholder proposals pursuant to Exchange Act Rule 14a-8 and communications made in connection with such proposals or (ii) service of process or any other business before the 2017 annual meeting must set forth certain information,notice in a legal proceeding.
Code of Ethics
We have adopted a Code of Business Conduct and Ethics (the “Code”) which, is specified inalong with our bylaws. A complete copy of our bylaws is available on our website www.galenabiopharma.com under Investors > Corporate Governance, which is not incorporated by reference.

25


Annex A

Certificate of Amendments to Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and the charters of Galena Biopharma, Inc.

Galena Biopharma,our Board committees, provides a framework for the governance of our company. The Board’s Nominating and Corporate Governance Committee is responsible for periodically reviewing our governance practices and principles. The Code applies to all of our directors, officers and employees.

The Code reflects current best practices and enhances our personnel’s understanding of our standards of ethical business practices, promotes awareness of ethical issues that may be encountered in carrying out an employee’s or director’s responsibilities, and provides clarity as to how to address ethical issues that may arise.
The foregoing description of the Code does not purport to be complete and is qualified in its entirety by reference to the full text of the Code, a copy of which is posted on our website at: https://ir.sellaslifesciences.com/corporate-governance/default.aspx. A printed copy may also be obtained by any stockholder upon request directed to SELLAS Life Sciences Group, Inc., Times Square Tower, 7 Times Square, Suite 2503, New York, NY 10036, Attention: Corporate Secretary. We also anticipate posting any future amendment or waiver of the Code on our website within four business days of the date of such amendment or waiver. The contents of our website are not incorporated by reference in this report or made a Delaware corporation (the “Corporation”), hereby certifies that:

part hereof for any purpose.
Executive Officers
The names and ages of our current executive officers and their positions are as follows:
Name1.The following resolution has been unanimously adopted by the Corporation’s Board of Directors and has been approved by the holders of a majority of the Corporation’s outstanding common stock in accordanceAgePosition with the Delaware General Corporation Law for the purpose of amending the Corporation’s Amended and Restated Certificate of Incorporation: RESOLVED, thatas follows:

.”

Company2.The above amendment was duly adopted by the Corporation in accordance with the provisions of Section 242 of the Delaware General Corporation Law.

IN WITNESS WHEREOF, Galena Biopharma, Inc. has caused this Certificate of Amendment to be signed by a duly authorized officer this         day of                 2016.

Galena Biopharma, Inc.

By:Angelos M. Stergiou, M.D., Sc.D. h.c./s/ MARK W. SCHWARTZ
48Mark W. Schwartz, Ph.D.
President, and Chief Executive Officer and Director
John T. Burns39Senior Vice President, Chief Financial Officer

1


LOGO

IMPORTANT SPECIAL MEETING INFORMATION 000004

ENDORSEMENT_LINE SACKPACK

MR A SAMPLE

DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4

ADD 5

ADD 6

C123456789

000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext

Electronic Voting Instructions

You can vote

Biographical Information Regarding Executive Officers
Set forth below is a biographical description of each executive officer based on information supplied by Internetsuch executive officer:
Angelos M. Stergiou, M.D., Sc.D. h.c., see “Board of Directors.”
John T. Burns.   Mr. Burns has served as the Company’s Senior Vice President, Chief Financial Officer since February 2023. Mr. Burns previously served as the Company’s Vice President, Finance, and Corporate Controller from December 2017 to December 2020, as Vice President, Finance, Corporate Controller and Principal Accounting Officer from January 2021 to December 2021 and as Senior Vice President, Finance, and Chief Accounting Officer from January 2022 to January 2023. Mr. Burns has over 15 years of experience in finance and accounting. Mr. Burns joined the Company in May 2013 and has held various positions of increasing responsibility during his tenure. Prior to joining the Company, Mr. Burns was a Securities and Exchange Reporting Manager at Pixelworks, Inc. (NASDAQ: PXLW), and began his career in public accounting at Moss Adams LLP. Burns received a B.S.M. in Finance and Master of Accounting degree from Tulane University. He is an active Certified Public Accountant.

21

TABLE OF CONTENTS

EXECUTIVE OFFICER AND DIRECTOR COMPENSATION
Summary Compensation Table
The following table shows the compensation paid or telephone! Available 24 hours a day, 7 days a week!

Instead of mailing your proxy, you may choose oneaccrued to our named executive officers (“NEOs”) for 2023 during the last two fiscal years ended December 31, 2023 and 2022. The NEOs are (i) our President and Chief Executive Officer, Angelos M. Stergiou, M.D., Sc.D. h.c., and (ii) our other two most highly compensated executive officers earning more than $100,000 who were serving as executive officers at the end of the two voting methods outlined belowyear ended December 31, 2023.

NameYear
Salary
($)
Non-Equity
Incentive
Plan
Compensation
($)(3)
Bonus
($)
Option
Awards
($)(1)
Stock
Awards
($)(2)
All Other
Compensation
($)
Total
($)
Angelos M. Stergiou, M.D., Sc.D. h.c.
President and Chief Executive Officer
2023625,000275,000654,675193,7204,243(5)1,752,638
2022593,500326,425795,300234,9602,060(5)1,952,245
Barbara Wood, Esq.
Former Executive Vice President, General Counsel and Corporate Secretary
2023442,000146,744240,80066,80017,576(7)913,920
2022425,000173,40020,000(4)234,97569,42014,260(8)937,055
John T. Burns
Senior Vice President, Chief Financial
Officer
2023365,000125,560225,75066,80014,598(7)797,708
2022310,000111,800173,52052,26413,260(8)659,844
(1)
The amounts reflected in this column represent the aggregate grant date fair value computed in accordance with ASC Topic 718. To determine the value of stock option awards, we use a Black Scholes pricing model to vote your proxy.

VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR.

Proxies submittedvalue stock options at the time of their grant. This model requires us to estimate the future value of our stock price based in part on the historic price volatility of our stock. See Note 12 to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, “Consolidated Financial Statements — Notes to Consolidated Financial Statements — Stock-Based Compensation,” for details as to the assumptions used to determine the fair value of equity awards.

(2)
The amounts reflected in this column represent the aggregate grant date fair value of restricted stock units computed in accordance with ASC Topic 718. The grant date fair value of restricted stock units is based on the closing price of our common stock on the date of grant.
(3)
For additional information regarding the non-equity incentive plan short-term compensation, see the section entitled “Non-Equity Incentive Plan Short Term Compensation.”
(4)
Represents a spot bonus award.
(5)
Represents the following Company benefits paid on behalf of the employee: medical, dental, vision, short-term/long-term liability insurances, education, basic life insurance, personal accident insurance, workers’ compensation insurance and employer liability insurance.
(7)
Represents 401(k) Plan matching contributions by the Internet or telephone must be received by 12:00 a.m., PSTCompany of $13,200 and benefits paid on October 21, 2016.

Vote by Internet

Go to www.envisionreports.com/GALE

Or scanbehalf of the QR code with your smartphone

Follow the steps outlined on the secure website

Vote by telephone

Call toll free 1-800-652-VOTE (8683) within the USA, US territories & Canada on a touch tone telephone

Follow the instructions providedemployee: medical, dental, vision, short-term/long-term liability insurances, education, basic life insurance, personal accident insurance, workers’ compensation insurance and employer liability insurance.

(8)
Represents 401(k) Plan matching contributions by the recorded message

A Proposals — Our BoardCompany of Directors recommends that you vote FOR$12,200 and benefits paid on behalf of the following proposals:

For Against Abstain

1. Proposalemployee: medical, dental, vision, short-term/long-term liability insurances, education, basic life insurance, personal accident insurance, workers’ compensation insurance and employer liability insurance.


22

TABLE OF CONTENTS

Narrative Disclosure to approve an amendmentSummary Compensation Table
Elements of Compensation
In addition to the 2. Proposaleach officer’s base salary, our executive officer compensation program consists of a cash incentive bonus plan and discretionary stock option awards in addition to authorize the issuance sharescustomary benefits. The amounts of compensation awarded for each element of the Company’s Amendedcompensation program (i.e., base salary, bonuses and Restated Certificatestock options) are reviewed in connection with the Company’s performance.
Base Salary
Annual base salaries compensate our executive officers for fulfilling the requirements of Company’s common stock issuable upontheir respective positions and provide them with a level of cash income predictability and stability with respect to a portion of their total compensation. We believe that the Incorporation (as amended from timelevel of an executive officer’s base salary should reflect the executive’s performance, experience and breadth of responsibilities, our understanding of salaries for similar positions within our industry and any other factors relevant to time,that particular job.
Base salaries are typically negotiated at the redemption, conversionoutset of an executive’s employment in connection with an offer of employment and employment agreement. Salary levels are considered annually as part of our performance review process, but also in cases including promotion or other satisfactionchanges in the job responsibilities of an executive officer. Merit and Company-wide general increases are also taken into consideration when determining increases to base salary.
Non-Equity Incentive Plan Short Term Compensation
For 2022 and 2023, short-term incentive cash compensation for our executive officers was determined based on the achievement of performance metrics related to our corporate goals. The corporate goals are proposed by senior management and reviewed and approved by our Compensation Committee and our Board on an annual basis at the start of each year. Our annual corporate goals are typically focused on the achievement of specified clinical development goals with a focus on advancing our clinical pipeline. The annual goals also usually include the pursuit of certain corporate development goals, such as business development initiatives and achievement of cash management strategies in order to assure adequate funding for our clinical development programs. The goals are designed to require significant effort in order to achieve our clinical development and operational goals while also being achievable with the requisite hard work and dedication. Awards made under our short-term cash incentive program utilize a pay-for-performance strategy and award our NEOs for the level of achievement of specified annual corporate goals, as well as individual goals for our NEOs other than our CEO whose short-term incentive compensation is based 100% on the level of achievement of our corporate goals.
Equity Grants
In February 2023, the Compensation Committee recommended, and our Board approved, the grant of 217,500, 80,000, and 75,000 options to Dr. Stergiou, Ms. Wood, and Mr. Burns, respectively, at an exercise price of $3.34 per share, which was the fair market value on the grant date. One quarter of the “Charter”),shares subject to effect a reversethese options vested in February 2024 and the remaining shares subject to the options will vest and become exercisable in equal monthly installments for 36 months thereafter. In February 2023, the Compensation Committee also recommended, and our Board approved, the grant of 58,000, 20,000, and 20,000 restricted stock splitunits to Dr. Stergiou, Ms. Wood, and Mr. Burns, respectively (the “2023 RSUs”). The 2023 RSUs vest 25% each December 1, commencing December 1, 2023, until fully vested, provided that the NEO remains in service with the Company through each such vesting date.
In January 2022, the Compensation Committee recommended, and our Board approved, the grant of 165,000, 48,750, and 36,000 options to Dr. Stergiou, Ms. Wood, and Mr. Burns, respectively, at an exercise price of $5.34 per share, which was the fair market value on the grant date. One quarter of the Company’s obligations under its Amendedshares subject to these options vested in January 2023 and Restated outstandingthe remaining shares subject to the options will vest and become exercisable in equal monthly installments for 36 months thereafter. In January 2022, the Compensation Committee also recommended, and our Board approved, the grant of 44,000, 13,000, and 9,600 restricted stock units to Dr. Stergiou, Ms. Wood, and Mr. Burns, respectively (the “2022 RSUs”). The 2022 RSUs vest

23

TABLE OF CONTENTS

25% each December 1, commencing December 1, 2022, until fully vested, provided that the NEO remains in service with the Company through each such vesting date.
Employment Agreements
We have entered into employment agreements with each of the Company’s common stock, 9% Original Issue Discount Senior Secured Debenture par value $0.0001 per share, at a ratio of not less due November 10, 2018, without the need for any than 1 for 2named executive officers described below, which include standard confidential information and/or inventions assignment agreements, and not greater than 1 for 20, with the limitation or cap on issuances as required by and in exact ratio and effective timeunder which each of the reverse stock splitnamed executive officers has agreed not to disclose our confidential information. The named executive officers are each eligible to participate in, subject to applicable eligibility requirements, all of our employee retirement and welfare benefit plans and programs made available to senior level executives. All severance benefits payable to the named executive officers under their employment agreements are subject to their signing, not revoking and complying with a release of claims in favor of us and are subject to applicable taxes and withholding.
Angelos M. Stergiou, M.D., Sc.D. h.c.
The 2019 Stergiou Agreement became effective as of July 1, 2019, at which time it replaced and superseded the 2016 Stergiou Agreement. The 2019 Stergiou Agreement has an initial two-year term unless terminated prior thereto (i) by us with cause (at any time) or without cause (upon at least 30 days’ prior written notice), or (ii) by Dr. Stergiou for good reason (upon at least 90 days prior written notice of the reason with a cure period of 30 days for us to correct the act or failure to act that constitutes good reason), or without good reason (upon at least 90 days prior written notice) or (iii) due to Dr. Stergiou’s death or disability. The 2019 Stergiou Agreement shall continue until terminated in accordance with NASDAQ Marketplace Rule 5635(d).its terms.
Pursuant to be determinedthe terms of the 2019 Stergiou Agreement, Dr. Stergiou is entitled to an annual base salary of $525,000 (subject to review and adjustment in the sole discretion of the Board or the compensation committee thereof) and a discretionary annual cash bonus, with a target amount no less than 50% of Dr. Stergiou’s then effective base salary (subject to continued employment and the achievement of certain performance objectives established by the Board of Directors and publicly announced by press release.

3. Proposal to authorize the adjournmentor Compensation Committee of the SpecialBoard). The agreement also provides that to the extent that any benefit distributable pursuant to the terms of the agreement would be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code of 1986, as amended (the “IRC”) , then the total payments payable to Dr. Stergiou will be reduced as set forth in the agreement (but not below zero) so that the maximum amount of such payments (after the reduction) shall be one dollar ($1.00) less than the amount which would cause such payments to be subject to the excise tax.

In addition, Dr. Stergiou is eligible to receive equity awards in the sole discretion of the Board or the Compensation Committee.
John T. Burns
Effective December 30, 2017, we entered into an employment agreement with Mr. Burns. Under this agreement, Mr. Burns is entitled to an annual base salary of $235,000 (subject to review and adjustment in the discretion of Company’s management team, the Board of Directors, or the Compensation Committee) and a discretionary annual cash bonus, with a target amount of up to 30% of Mr. Burns’ then-effective base salary. In connection with Mr. Burns’ appointment as Chief Financial Officer on February 2, 2023, Mr. Burns’ base salary was increased to $365,000 per year, and his annual target bonus was increased to 40% of his base salary.
Pursuant to the terms of his employment agreement, Mr. Burns is eligible to purchase stock options pursuant to and in accordance with the terms and conditions of a stock incentive plan upon adoption of said stock incentive plan by us and the Board of Directors. In addition, Mr. Burns is eligible to participate in any employee benefit plans of the Company of general applicability to other of our employees including, without limitation, group medical, dental, vision, disability, life insurance, and flexible spending account plans.
Mr. Burns’ employment agreement does not have a specified term and may be terminated (i) by us with or without cause at any time or (ii) by Mr. Burns with or without cause upon at least 45 days’ prior written

24

TABLE OF CONTENTS

notice. In December 2021, we entered into a severance agreement with Mr. Burns (the “Burns Severance Agreement”) pursuant to which Mr. Burns is entitled to receive additional compensation in the event that Mr. Burns’ employment is terminated under certain conditions. See the discussion below under “Potential Payments Upon Termination or Change of Control.” In addition to the payment of severance amounts, the Burns Severance Agreement also provides that to the extent that any benefit distributable pursuant to the terms of the Burns Severance Agreement would be subject to the excise tax imposed under Section 4999 of the IRC, then the total payments payable to Mr. Burns shall be reduced as set forth in the Burns Severance Agreement (but not below zero) so that the maximum amount of such payments (after the reduction) shall be one dollar ($1.00) less than the amount which would cause such payments to be subject to the excise tax.
Barbara A. Wood, Esq.
Effective March 14, 2018, we entered into an employment letter agreement with Ms. Wood. Under this agreement, Ms. Wood was entitled to an annual base salary of $365,000 (subject to review and adjustment in the discretion of the Board of Directors or the Compensation Committee) and a discretionary annual cash bonus, with a target amount of up to 40% of Ms. Wood’s then-effective base salary (subject to continued employment and the achievement of certain performance objectives established by our Board or Compensation Committee).
In connection with Ms. Wood entering into her employment letter agreement, and pursuant to the terms thereof, we granted to Ms. Wood incentive stock options to purchase up to 1,000 shares of our common stock. The option has an exercise price equal to the market price of our common stock upon the date of grant and vests as to one quarter after one year from grant and with the remainder over 36 equal monthly installments thereafter, so that the option will be fully vested and exercisable four years from the date of grant.
Ms. Wood’s employment letter agreement did not have a specified term and either party was permitted to terminate Ms. Wood’s employment agreement by providing written notice at any time, with or without cause. In December 2018, we entered into a severance agreement with Ms. Wood (the “Wood Severance Agreement”) pursuant to which Ms. Wood was entitled to receive additional compensation in the event that Ms. Wood’s employment was terminated under certain conditions. See the discussion below under “Potential Payments Upon Termination or Change of Control.” In addition to the payment of severance amounts, the Wood Severance Agreement also provided that to the extent that any benefit distributable pursuant to the terms of the Wood Severance Agreement would be subject to the excise tax imposed under Section 4999 of the IRC, then the total payments payable to Ms. Wood shall be reduced as set forth in the Wood Severance Agreement (but not below zero) so that the maximum amount of such payments (after the reduction) shall be one dollar ($1.00) less than the amount which would cause such payments to be subject to the excise tax.
On March 27, 2024, we entered into a Separation and General Release Agreement with Ms. Wood (the “Wood Separation Agreement”). Pursuant to the terms of the Wood Separation Agreement, we agreed to pay Ms. Wood an amount equal to (i) 12 months of her base salary, plus (ii) an amount equal to a pro-rated portion of Ms. Wood’s annual short-term incentive compensation at the applicable target level for the year of 2024. Additionally, the Company will pay for Ms. Wood’s COBRA health insurance benefits commencing with the separation date and continuing for the earlier of (i) the 12-month anniversary of the separation date and (ii) the end of the calendar month in which Ms. Wood becomes eligible to participate in a subsequent employer’s group health plan. Under the Wood Separation Agreement, the deadline for Ms. Wood to exercise any stock options granted under the 2017 Equity Incentive Plan and 2023 Amended and Restated Equity Incentive Plan has been extended to six months after the separation date, and we agreed to pay Ms. Wood for her accrued, but unused, vacation. Furthermore, Ms. Wood has provided general releases and other confidentiality covenants to us in connection with her departure.
Potential Payments Upon Termination or Change of Control
Angelos M. Stergiou
Potential Payments Made Upon Termination with Cause or Without Good Reason.   The 2019 Stergiou Agreement provides that if Dr. Stergiou’s employment is terminated with cause by us, or by Dr. Stergiou

25

TABLE OF CONTENTS

without good reason, we will pay Dr. Stergiou all his accrued benefits, and all other rights and benefits of Dr. Stergiou will terminate upon such termination, except for any right to the continuation of benefits otherwise provided by law.
Potential Payments Made Upon Termination Without Cause or for Good Reason.   The 2019 Stergiou Agreement provides that if we terminate Dr. Stergiou’s employment without cause or Dr. Stergiou resigns for good reason, we will pay Dr. Stergiou the following amounts in equal installments over a defined 12 month period: (i) an amount equal to 18 months of his then-current base salary, less standard employment-related withholdings and deductions and (ii) an amount equal to a pro-rated portion of his annual short-term incentive compensation for the year in which his employment terminates, without regard to whether the performance goals with respect to such bonus have been established or met and less standard employment-related withholdings and deductions. In addition, Dr. Stergiou will be entitled, if he so elects, to receive reimbursement for Consolidated Omnibus Budget Reconciliation Act of 1986 (“COBRA”) monthly premiums for a specified period of time.
Potential Payments Upon Termination Related to Change in Control.   The 2019 Stergiou Agreement provides that if we terminate Dr. Stergiou’s employment without cause or he resigns for good reason within a one month period prior to or one year following a change in control we will pay him the following amounts in equal installments over a 12 month period: (i) an amount equal to 24 months of his then-current base salary, less standard employment-related withholdings and deductions; and (ii) an amount equal to one and one-half times his target bonus for the year in which his employment terminates, without regard to whether the performance goals with respect to such target bonus have been established or met and less standard employment-related withholdings and deductions. In addition, Dr. Stergiou will be entitled, if he so elects, to receive reimbursement for COBRA monthly premiums for a specified period of time. Furthermore, the vesting of all of his equity awards will immediately vest in full and become exercisable as of the date of termination.
John T. Burns
Potential Payments Made Upon Termination with Cause or Without Good Reason.   Pursuant to the terms of the Burns Employment Agreement, commencing on the 18-month anniversary of the effective date of the Burns Employment Agreement, in the event that Mr. Burns’ employment is terminated by us without cause or by Mr. Burns for good reason, we will pay Mr. Burns an amount equal to nine months of his then-current base salary, less standard employment-related withholdings and deductions.
Potential Payments Upon Termination Related to Change in Control.   The Burns Severance Agreement provides that if we terminate Mr. Burns’ employment without cause or he resigns for good reason within one year following a change in control, we will pay him the following amounts in equal installments over a 12 month period: (i) an amount equal to 12 months of his then-current base salary, less standard employment-related withholdings and deductions; and (ii) an amount equal to his target bonus for the year in which his employment terminates, without regard to whether the performance goals with respect to such target bonus have been established or met and less standard employment-related with holdings and deductions. In addition, Mr. Burns will be entitled, if he so elects, to receive reimbursement for COBRA monthly premiums for a specified period of time.
Barbara A. Wood, Esq.
Potential Payments Made Upon Termination Without Cause or for Good Reason.   Pursuant to the terms of the Wood Severance Agreement, in the event that Ms. Wood’s employment is terminated by us without cause or by Ms. Wood for good reason, we will pay Ms. Wood the following amounts in equal installments over a 12- month period: (i) an amount equal to 12 months of the then-current base salary, less standard employment-related withholdings and deductions, and (ii) an amount equal to a pro-rated portion of Ms. Wood’s annual short-term incentive compensation for the year in which the employment terminates, without regard to whether the performance goals with respect to such bonus have been have been established or met and less standard employment-related withholdings and deductions. In addition, Ms. Wood will be entitled, if she so elects, to receive reimbursement for COBRA monthly premiums for a specified period of time. For discussion of payments to be made pursuant to the Wood Separation Agreement, see “Employment Agreements — Barbara A. Wood, Esq.” above.

26

TABLE OF CONTENTS

Potential Payments Upon Termination Related to Change in Control.   The Wood Severance Agreement provides that if we terminate Ms. Wood’s employment without cause or she resigns for good reason within one year following a change in control we will pay her the following amounts in equal installments over a 18 month period: (i) an amount equal to 18 months of her then-current base salary, less standard employment-related withholdings and deductions; and (ii) an amount equal to her target bonus for the year in which her employment terminates, without regard to whether the performance goals with respect to such target bonus have been established or met and less standard employment-related with holdings and deductions. In addition, Ms. Wood will be entitled, if she so elects, to receive reimbursement for COBRA monthly premiums for a specified period of time.
Outstanding Equity Awards At 2023 Fiscal Year-End
The following table discloses certain information regarding all outstanding equity awards at fiscal year-end for each of the officers named in the Summary Compensation Table.
Name
Grant
Date
Number of
Securities
Underlying
Unexercised
Options
Exercisable
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable(1)
Option
Exercise
Price
($)(2)
Option
Expiration
Date
Number of
Shares or
Units of
Stock That
Have Not
Vested (#)(3)
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested ($)(4)
Angelos M. Stergiou03/13/20181,900$262.0003/13/2028
03/18/20198,500$69.0003/18/2029
03/12/202065,6254,375$1.8903/12/2030
03/12/202095,000$100,700
03/04/202181,46937,031$8.0003/04/2031
03/04/20214,937$5,233
01/31/202279,06385,938$5.3401/31/2032
01/31/202222,000$23,320
02/02/2023217,500$3.3402/02/2033
02/02/202343,500$46,110
Barbara A. Wood03/14/20181,000$255.0003/14/2028
03/18/20193,300$69.0003/18/2029
03/12/202023,4381,563$1.8903/12/2030
03/12/202035,000$37,100
03/04/202132,48414,766$8.0003/04/2031
03/04/20211,968$2,086
01/31/202223,35925,391$5.3401/31/2032
01/31/20226,500$6,890
02/02/202380,000$3.3402/02/2033
02/02/202315,000$15,900
John T. Burns03/13/2018400$262.0003/14/2028
03/18/20191,800$69.0003/18/2029
03/12/20209,375625$1.8903/12/2030
03/12/202015,000$15,900
03/04/202111,8595,391$8.0003/04/2031
03/04/2021718$761
01/31/202217,25018,750$5.3401/31/2032
01/31/20224,800$5,088
02/02/202375,000$3.3402/02/2033
02/02/202315,000$15,900

27

TABLE OF CONTENTS

(1)
These unvested shares underlying each option grant are scheduled to vest at a rate of one quarter on the first anniversary of the grant date and with the remainder over 36 equal monthly installments.
(2)
The exercise price was determined by using the market price for our common stock at the close of business on the grant date.
(3)
The March 2020 RSUs are scheduled to vest as follows: (i) 50% on meeting the primary endpoint in our Phase 3 REGAL study for GPS and (ii) 50% upon approval by the FDA of a BLA for GPS. The March 2021 RSUs vest 25% on each December 1, commencing December 1, 2021, until fully vested, provided that the Reporting Person remains in service with the Company through each such vesting date. The January 2022 RSUs vest 25% on each December 1, commencing December 1, 2022, until fully vested, provided that the Reporting Person remains in service with the Company through each such vesting date. The February 2023 RSUs vest 25% on each December 1, commencing December 1, 2023, until fully vested, provided that the Reporting Person remains in service with the Company through each such vesting date.
(4)
Each RSU entitles the holder thereof to receive one share of our common stock for each RSU granted upon vesting or settlement. The market value is calculated by multiplying $1.06, the closing price of a share of our common stock on December 29, 2023, the last trading day of the year, as reported on Nasdaq, by the number of unvested units.
Pay versus Performance
As required by SEC rules, we are providing the following information about the relationship between executive compensation actually paid and our financial performance.
Year(a)
Summary
Compensation
Table Total
for PEO(b)
Compensation
Actually Paid
to PEO(c)
Average
Summary
Compensation
Table Total
for Non-PEO
NEOs(d)
Average
Compensation
Actually Paid
to
Non-PEO
NEOs(e)
Value of Initial
Fixed
$100 Investment
Based On
Total Shareholder
Return(f)
Net Loss
(thousands)(g)
2023$1,752,638$801,284$855,814536,56144.92$(37,340)
2022$1,952,245$667,297$995,219514,53642.68$(41,301)
2021$1,833,917$1,615,812$911,937935,76895.18$(20,699)
(a)
Dr. Stergiou served as our Principal Executive Officer (“PEO”) in both years presented. For 2023, Ms. Wood and Mr. Burns served as our other NEOs. For 2022, Ms. Wood and Mr. Robert Francomano served as our other NEOs.
(b)
The dollar amounts reported in column (b) represent the amount of total compensation reported for Dr. Stergiou (our PEO) for each corresponding year in the “Total” column of the Summary Compensation Table.
(c)
The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Dr. Stergiou. The amounts are computed in accordance with SEC rules by deducting and adding the following amounts from the “Total” column of the Summary Compensation Table (pursuant to SEC rules, fair value at each measurement date is computed in a manner consistent with the fair value methodology used to account for share-based payments in our financial statements under GAAP). The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr. Stergiou during the applicable year.
Year
Reported
Summary
Comp Table
Total
for PEO
Reported
Value of
Equity
Awards(1)
Equity
Award
Adjustments(2)
Compensation
Actually
Paid to
PEO
2023$1,752,638$(848,395)$(102,959)$801,284
2022$1,952,245$(1,030,260)$(254,688)$667,297
2021$1,833,917$(985,887)$767,782$1,615,812

28

TABLE OF CONTENTS

(1)
The dollar amounts reported are the total value of equity awards for Dr. Stergiou for each corresponding year in the “Option Awards” and “Stock Awards” columns of the Summary Compensation Table.
(2)
The amounts deducted or added in calculating the equity award adjustments are as follows:
Year
Year End
Fair Value
of
Outstanding
and
Unvested
Equity
Awards
Granted in
the Year
Year over
Year
Change in
Fair Value of
Outstanding
and
Unvested
Equity
Awards
Granted in
Prior Years
Fair Value as
of Vesting
Date of Equity
Awards Granted
and Vested in
the Year
Year over
Year
Change in Fair
Value of
Equity
Awards
Granted in
Prior Years
that Vested in
the Year
Total Equity
Award
Adjustments
2023$238,628$(315,187)$15,660$(42,060)$(102,959)
2022$413,468$(606,744)$28,600$(90,012)$(254,688)
2021$666,308$(46,816)$31,057$117,233$767,782
(d)
The dollar amounts reported in column (d) represent the average of the amounts reported for the Company’s non-PEO NEOs for each corresponding year in the “Total” column of the Summary Compensation table.
(e)
The dollar amounts reported in column (e) represent the average amount of “compensation actually paid” to the Company’s non-PEO NEOs, as computed in accordance with SEC rules by deducting and adding the following amounts from the “Total” column of the Summary Compensation Table using the same methodology described above in Note (c)2. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the Company’s non-PEO NEOs during the applicable year.
Year
Average Reported
Summary
Compensation
Table Total for
Non-PEO NEOs
Average Reported
Value of
Equity Awards(1)
Average Equity Award
Adjustments(2)
Average Compensation
Actually Paid to
Non-PEO NEOs
2023$855,814$(300,075)$(19,178)$536,561
2022$995,219$(388,187)$(92,496)$514,536
2021$911,937$(393,107)$416,938$935,768
(1)
The dollar amounts reported are the total value of equity awards for the non-PEO NEOs for each corresponding year in the “Option Awards” and “Stock Awards” columns of the Summary Compensation Table.
(2)
The amounts added (or deducted, if applicable) in calculating the total average equity award adjustments in each applicable year are as follows:
Year
Average
Year End
Fair Value
of
Outstanding
and
Unvested
Equity
Awards
Granted in
the Year
Year over
Year Average
Change in
Fair Value of
Outstanding
and
Unvested
Equity
Awards
Granted in
Prior Years
Fair Value as
of Vesting
Date of Equity
Awards Granted
and Vested in
the Year
Year over
Year Average
Change in Fair
Value of
Equity Awards
Granted in
Prior Years
that Vested in
the Year
Total Average
Equity
Award
Adjustments
2023$69,008$(82,509)$5,400$(11,077)$(19,178)
2022$163,465$(229,926)$8,450$(34,484)$(92,496)
2021$265,680$82,467$12,383$56,408$416,938

29

TABLE OF CONTENTS

(f)
Cumulative Total Shareholder Return (“TSR”) measures the cumulative value of $100 invested on the last trading day before the earliest fiscal year in the table, or December 31, 2020, including the reinvestment of dividends, through and including the end of the applicable fiscal year for which TSR is calculated, or December 31, 2021, 2022, and 2023. We did not pay dividends in the periods presented.
(g)
The dollar amounts reported represent the amount of net loss reflected in the Company’s audited financial statements for the applicable year.
Relationship between Compensation Actually Paid and the Company’s Net Loss and Total Shareholder Return
As described in more detail in the section “Narrative Disclosure to Summary Compensation Table,” the Company’s executive compensation program reflects a variable pay-for-performance philosophy. Because we are not a commercial-stage company, we did not have any revenue during the periods presented, other than milestone-based licensing revenue in the reported years. Consequently, the Company has not historically looked to net income (loss) as a performance measure for our executive compensation program. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with compensation that is actually paid (as computed in accordance with SEC rules) for a particular year. A large component of our executive compensation is equity-based to align compensation with performance, but compensation also includes other appropriate incentives such as cash bonuses that are designed to incentivize our executives to achieve annual corporate goals. In accordance with SEC rules, the Company is providing the following descriptions of the relationships between information presented in the Pay versus Performance table above.
As demonstrated by the following graph, the amount of compensation actually paid to Dr. Stergiou and the average amount of compensation actually paid to the Company’s non-PEO NEOs is generally aligned with the Company’s net loss for the past three years. Between 2021 and 2023, our net loss increased, and the compensation actually paid for both our PEO and our non-PEO NEOs decreased.
[MISSING IMAGE: bc_netloss-4c.jpg]

30

TABLE OF CONTENTS

As demonstrated by the following graph, the amount of compensation actually paid to Dr. Stergiou and the average amount of compensation actually paid to the Company’s non-PEO NEOs is generally aligned with the Company’s total shareholder return for the past three years.
[MISSING IMAGE: bc_paidtsr-4c.jpg]
Director Compensation
The following table shows the total compensation paid or accrued during the fiscal year ended December 31, 2023 to each of our non-employee directors. Directors who are employed by us are not compensated for their service on our Board of Directors.
Name
Fees Earned or
Paid in Cash ($)(1)
Option
Awards ($)(2)
Stock Awards
($)(3)
Total
($)(4)
Jane Wasman99,78028,1518,350136,281
Robert L. Van Nostrand69,78028,1518,350106,281
John Varian74,00028,1518,350110,501
David A. Scheinberg66,00028,1518,350102,501
Katherine Bach Kalin56,00028,1518,35092,501
(1)
Represents cash compensation earned or paid for services rendered by each non-employee director for services on our Board or a committee thereof.
(2)
Amounts shown reflect the grant date fair value computed in accordance with FASB ASC 718, adjusted to disregard the effects of any estimate of forfeitures related to service-based vesting. Each director received 9,500 stock options on February 2, 2023. The assumptions we used in valuing options are described more fully in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in the footnotes to our financial statements incorporated in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
(3)
The amounts reflected in this column represent the aggregate grant date fair value of restricted stock units computed in accordance with ASC Topic 718. The grant date fair value of restricted stock units is based on the closing price of our common stock on the date of grant.
(4)
Dr. Angelos M. Stergiou, our Chief Executive Officer, is also a member of our Board, but does not receive any additional compensation for his service as a director.

31

TABLE OF CONTENTS

Director Compensation Policy
Non-Employee Director Compensation Policy
Upon the recommendation of the Compensation Committee, the Board adopted a formal Non-Employee Director Compensation Policy, effective as of March 2, 2023.
The Non-Employee Director Compensation Policy provides for the following compensation for our directors:
Compensation CategoryAmount
Annual Base Compensation$40,000
Additional Non-Executive Chair Compensation$30,000
Additional Committee Chair Compensation:
Audit$18,000
Compensation$18,000
Nominating and Corporate Governance$18,000
Science$18,000
Additional Committee Membership Compensation:$18,000
Audit$8,000
Compensation$8,000
Nominating and Corporate Governance$8,000
Science$8,000
The annual cash compensation will be benchmarked annually against that of the Company’s peer group and is subject to adjustment following such review.
The Non-Employee Director Compensation Policy also provides for equity compensation as follows:
Initial Grant:   Each Non-Employee Director who is initially elected or appointed to the Board is entitled to receive a non-qualified stock option in an amount equal to two times the number of stock option equivalents under the most recent annual equity grant (described below) preceding the initial election or appointment. The initial grant will vest in 36 successive equal monthly installments over a three-year period measured from the date of grant.
Annual Grant:   A Non-Employee Director who has been serving as a Non-Employee Director on the Board for at least six months as of the date of the annual equity grants to the Non-Employee Directors shall be automatically granted a non-qualified stock option grant and a restricted stock unit (“RSU”) award. Each annual option grant will vest in full on the earlier of the first anniversary of the date of grant, or the business day prior to the annual meeting of stockholders occurring the year following the year of grant, subject to the Non-Employee Director’s continued service on the Board through such date. The annual RSU award will vest in full on December 1 of the year in which the grant is made, subject to the Non-Employee Director’s continued service on the Board through such date.
The value underlying the annual equity grants will be benchmarked annually against that of the Company’s peer group and is subject to adjustment following such review.
Securities Authorized for Issuance Under Equity Compensation Plans
The following table provides certain aggregate information with respect to all of the Company’s equity compensation plans in effect as of December 31, 2023.

32

TABLE OF CONTENTS

Equity Compensation Plan Information as of December 31, 2023
Plan Category
Number of Securities to be
Issued upon Exercise of
Outstanding Options, Warrants
and Rights
Weighted
Average
Exercise
Price of
Outstanding
Options,
Warrants and
Rights
Number of Securities
Remaining Available for
Future Issuance under
Equity Compensation
Plans (Excluding
Securities Reflected in
Previous Columns)
Equity compensation plans approved by security holders
2017 Equity Incentive Plan21,520$112.85
2023 Amended and Restated Equity Incentive Plan Stock1,923,424$4.47(1)3,950,528
2021 Employee Stock Purchase PlanN/A183,457
Equity compensation plans not approved by
security holders
None
Total21,520112.85
(1)
Represents the weighted average exercise price of outstanding stock options.
Related Person Transactions Policy and Procedures
We have adopted a written Related Person Transactions and SEC Compliance Policy that sets forth our policies and procedures regarding the identification, review, consideration and approval or ratification of “related persons transactions.” For purposes of our policy only, a “related person transaction” is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any “related person” are participants involving an amount that exceeds $120,000. Transactions involving compensation for services provided to us as an employee, director, consultant or similar capacity by a related person are not covered by this policy. A related person is any executive officer, director, or more than 5% stockholder, including any of their immediate family members, and any entity owned or controlled by such persons.
Under the policy, where a transaction has been identified as a related person transaction, management must present information regarding the proposed related person transaction to our Audit Committee (or, where Audit Committee approval would be inappropriate, to another independent body of our Board) for consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits of the transaction to us and whether any alternative transactions were available. To identify related person transactions in advance, we rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related person transactions, our Audit Committee takes into account the relevant available facts and circumstances including, but not limited to (a) the risks, costs and benefits to us, (b) the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated, (c) the terms of the transaction, (d) the availability of other sources for comparable services or products and (e) the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. In the event a director has an interest in the proposed transaction, the director must recuse himself or herself form the deliberations and approval. The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our Audit Committee consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our Audit Committee determines in the good faith exercise of its discretion.

33

TABLE OF CONTENTS

PROPOSAL 1
ELECTION OF DIRECTORS
Our Board of Directors currently consists of six (6) members, classified into three classes as follows: (1) Jane Wasman and Robert Van Nostrand are members of Class I with a term ending at the 2026 annual meeting; (2) David A. Scheinberg and Katherine Bach Kalin are members of Class II with a term ending at the 2024 Annual Meeting; and (3) Angelos M. Stergiou and John Varian are members of Class III with a term ending at the 2025 annual meeting. At each annual meeting of stockholders, directors are elected for a full term of three years to succeed those directors whose terms are expiring. Our Board of Directors is nominating David A. Scheinberg and Katherine Bach Kalin for election at the 2024 Annual Meeting as Class II directors to serve for terms of three years until his or her death, resignation, or removal pursuant to our Bylaws.
Unless authority to vote for these nominees is withheld, the shares represented by proxies solicited by the Board will be voted “FOR” the election of the foregoing Class II directors. In the event that the foregoing nominees become unable or unwilling to serve, the shares represented by proxies solicited by the Board will be voted for the election of such other person(s) as our Board of Directors may recommend in that respective nominee’s place. We have no reason to believe that the foregoing nominees will be unable or unwilling to serve as directors.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THE ELECTION OF DAVID A. SCHEINBERG AND KATHERINE BACH KALIN AS CLASS II DIRECTORS, AND PROXIES SOLICITED BY OUR BOARD OF DIRECTORS WILL BE VOTED IN FAVOR THEREOF, UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE ON THE PROXY.

34

TABLE OF CONTENTS

PROPOSAL 2
RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM
The Audit Committee of our Board has appointed Moss Adams LLP (“Moss Adams”), as our independent registered public accounting firm for the fiscal year ended December 31, 2024, and has further directed that management submit the appointment of its independent registered public accounting firm for ratification by the stockholders at the 2024 Annual Meeting.
Moss Adams currently serves as our independent registered public accounting firm and audited our financial statements for the year ended December 31, 2023. Moss Adams has served as our auditors since 2018. Moss Adams does not have and has not had any financial interest, direct or indirect, in our Company, and does not have and has not had any connection with our company except in its professional capacity as our independent auditors.
Our Audit Committee and our Board believe that the continued retention of Moss Adams to serve as our independent registered public accounting firm is in the best interests of the Company and its stockholders. As a matter of good corporate governance, we are asking stockholders to ratify such appointment. If this appointment is not ratified at the 2024 Annual Meeting, the Audit Committee intends to reconsider its selection of Moss Adams. Even if necessarythe appointment is ratified, the Audit Committee in its sole discretion may direct the appointment of a different independent registered public accounting firm at any time during the fiscal year if the Audit Committee determines that such a change would be in the best interests of our company and its stockholders.
Audit and non-audit services to be provided by Moss Adams are subject to the prior approval of the Audit Committee. In general, the Audit Committee’s policy is to grant such approval where it determines that the non-audit services are not incompatible with maintaining the independent registered public accounting firm’s independence and there are costs or appropriate,other efficiencies in obtaining such services from the independent registered public accounting firm as compared to other possible providers. Representatives of Moss Adams are expected to be present at the 2024 Annual Meeting, will have an opportunity to make a statement if they desire to do so, and will be available to respond to questions.
Our Audit Committee is directly responsible for appointing, compensating and providing oversight of the performance of our independent registered public accounting firm for the purpose of issuing audit reports and related work regarding our financial statements and the effectiveness of our internal control over financial reporting. The Audit Committee is also responsible for approving the audit and non-audit fees of our independent registered public accounting firm. In order to assure continuing auditor independence, the Audit Committee periodically considers whether there should be a regular rotation of the independent registered public accounting firm.
“FOR” votes from the majority of the votes cast is required to ratify the appointment of Moss Adams. Abstentions and broker non-votes will count towards a quorum but will have no effect on the outcome of this Proposal 2.
Principal Accountant Fees and Services
The following table represents aggregate fees billed to us for the years ended December 31, 2023 and 2022, by Moss Adams, our independent registered principal accounting firm.
20232022
(in thousands)
Audit Fees(1)
$457$416
Audit-related Fees(2)
103187
Tax Fees(3)
3337
All Other Fees
Total Fees$593$640

35

TABLE OF CONTENTS

(1)
For the years ended December 31, 2023 and 2022, the aggregate audit fees billed for professional services rendered for audits and quarterly reviews of our consolidated financial statements.
(2)
For the years ended December 31, 2023 and 2022, audit-related fees billed by Moss Adams pertained to services rendered in connection with procedures required for filings with the SEC in conjunction with financing transactions.
(3)
Tax fees consist of fees for tax consultation and compliance services.
All fees described above were pre-approved by the Audit Committee.
We furnished the foregoing disclosure to Moss Adams.
Pre-Approval Procedures
Our Audit Committee pre-approves of audit and non-audit services rendered by our independent registered public accounting firm, Moss Adams. Our Audit Committee pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. Pre-approval may also be given as part of our Audit Committee’s approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is present,engaged to provide each service.
Our Audit Committee has determined that the rendering of services other than audit services by Moss Adams is compatible with maintaining the principal accountant’s independence.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE TO RATIFY THE APPOINTMENT OF MOSS ADAMS AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, AND PROXIES SOLICITED BY OUR BOARD OF DIRECTORS WILL BE VOTED IN FAVOR OF SUCH RATIFICATION, UNLESS A STOCKHOLDER INDICATES OTHERWISE ON THE PROXY.

36

TABLE OF CONTENTS

PROPOSAL 3
TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF
OUR NAMED EXECUTIVE OFFICERS
At our 2019 annual meeting of stockholders, the stockholders indicated their preference that we solicit additional proxies if therea non-binding advisory vote on the compensation of our named executive officers, commonly referred to as a “say-on-pay vote,” every year. The Board of Directors adopted a policy that is consistent with that preference. In accordance with that policy, this year, we are insufficientagain asking the stockholders to approve, on an advisory basis, the compensation of our named executive officers as disclosed in this Proxy Statement in accordance with SEC rules.
At the 2023 annual meeting, we sought an advisory “say-on-pay” vote on our Company’s executive compensation program. The 2023 say-on-pay proposal was approved by approximately 60% of the votes cast at the Special Meetingmeeting.
Our Compensation Committee and Management are committed to considering and being responsive to stockholder views on executive compensation. We continue to re-evaluate our pay practices and compensation programs with guidance from our independent compensation consultant, Radford. Additionally, in favor2022 and, even more robustly, in 2023, Dr. Stergiou, as well as other members of management, have engaged in stockholder outreach, including periodically engaging with stockholders and participating in investor conferences which have provided them with the opportunity to understand stockholder views on the status of the ReverseCompany’s clinical trial programs, financial performance, strategic business plans, corporate governance, executive compensation, and related subjects.
In connection with our shareholder outreach in 2023, we contacted ten of our largest identifiable retail investors and five institutional investors. Subsequently, we engaged in active discussions with five of those investors who agreed to meet with us. Through the course of conducting these meetings, we received helpful and constructive feedback on a range of topics, including the composition of the Board and committees, executive compensation (e.g., our 2021 Employee Stock Split.

B Non-Voting Items

UsingPurchase Plan and stock ownership guidelines), and corporate overview/updates. The stockholders appreciated that a black ink pen, mark yourmechanism is in place to purchase shares through the Employee Stock Purchase Plan. In addition, the stockholders we engaged with generally noted that our executive compensation program aligned with expectations and did not have concerns about our executive compensation program. There were some questions about our stock ownership guidelines and executive share purchases and ownership. The Company will review and consider stockholders’ feedback as it makes future compensation and governance decisions.

The 2024 say-on-pay vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this Proxy Statement. The compensation of our named executive officers subject to the vote is disclosed in the compensation tables and the related narrative disclosure contained in this Proxy Statement. We believe that our compensation policies and decisions are focused on pay-for-performance principles, strongly aligned with our stockholders’ interests and effective in achieving the overall objectives of our compensation program. Compensation of our named executive officers is designed to enable us to attract and retain talented and experienced executives to lead us successfully in a competitive environment.
Accordingly, our Board is asking the stockholders to indicate their support for the compensation of our named executive officers as described in this Proxy Statement by casting a non-binding advisory vote “FOR” the following resolution:
“RESOLVED, that the compensation paid to our named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion is hereby APPROVED.”
Because the vote is advisory, it is not binding on the Board. Nevertheless, the views expressed by the stockholders, whether through this vote or otherwise, are important to management and the Board and, accordingly, our Board and our Compensation Committee intend to consider the results of this vote in making determinations in the future regarding executive compensation arrangements.

37

TABLE OF CONTENTS

Although there is no “required vote” that would constitute approval for this Proposal 3, non-binding advisory approval of this Proposal 3 requires that the proposal receive “FOR” votes from the holders of a majority of the shares voting online or represented by proxy and entitled to vote on the matter at the 2024 Annual Meeting that cast votes with respect to this Proposal 3. Abstentions and broker non-votes will count towards a quorum but will have no effect on the outcome of this Proposal 3. Unless the Board decides to modify its policy regarding the frequency of soliciting advisory votes on the compensation of our named executive officers, the next scheduled say-on-pay vote will be at the 2025 annual meeting of stockholders.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AND PROXIES SOLICITED BY OUR BOARD OF DIRECTORS WILL BE VOTED IN FAVOR OF SUCH APPROVAL, UNLESS A STOCKHOLDER INDICATES OTHERWISE ON THE PROXY.

38

TABLE OF CONTENTS

OTHER MATTERS
The Board, at the time of the preparation of this Proxy Statement, knows of no other matters to come before the 2024 Annual Meeting other than that referred to herein. If any other matters should properly come before the 2024 Annual Meeting, the persons acting as proxies will have discretionary authority to vote all proxies in accordance with their best judgment.
By Order of the Board of Directors
[MISSING IMAGE: sg_angelosmstergiou-bw.jpg]
Angelos M. Stergiou, M.D., Sc.D. h.c.
President and Chief Executive Officer

39

TABLE OF CONTENTS
[MISSING IMAGE: px_24sellasproxy1pg1-bw.jpg]
SCAN TOVIEW MATERIALS & VOTE SELLAS LIFE SCIENCES GROUP, INC.VOTE BY INTERNET7 TIMES SQUARE, SUITE 2503NEW YORK, NEW YORK 10036Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode aboveUse the Internet to transmit your voting instructions and for electronic delivery ofinformation up until 11:59 p.m. Eastern Time on June 19, 2024. Have your proxycard in hand when you access the web site and follow the instructions to obtain yourrecords and to create an X as shownelectronic voting instruction form.During The Meeting - Go to www.virtualshareholdermeeting.com/SLS2024You may attend the meeting via the Internet and vote during the meeting. Have theinformation that is printed in this example. Please do not write outside the designated areas.

Special Meeting Proxy Card 1234 5678 9012 345

IF YOU HAVE NOT VOTED VIA THE INTERNETbox marked by the arrow available and follow theinstructions.VOTE BY PHONE - 1-800-690-6903Use any touch-tone telephone to transmit your voting instructions up until11:59 p.m. Eastern Time on June 19, 2024. Have your proxy card in hand when youcall and then follow the instructions.VOTE BY MAILMark, sign and date your proxy card and return it in the postage-paid envelope wehave provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way,Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACHBLACK INK AS FOLLOWS:V42908-P10008THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.SELLAS LIFE SCIENCES GROUP, INC.The Board of Directors recommends you vote FOR the following: KEEP THIS PORTION FOR YOUR RECORDSDETACH AND RETURN THE BOTTOMTHIS PORTION IN THE ENCLOSED ENVELOPE.

ChangeONLY 1.To elect two (2) Class II directors to serve on our Board for a three-year term expiring in 2027. Nominees:ForWithhold1a.David A. Scheinberg!!1b.Katherine Bach Kalin!!2.To ratify the appointment by our Audit Committee of Address — Please print new address below. Meeting Attendance

Mark box toMoss Adams LLP as our independent registered public accounting firm for the right if you plan to attendfiscal year ending December 31, 2024. 3.To approve, on an advisory basis, the Special Meeting.

C Authorized Signatures — This section must be completed for your vote to be counted. — Date and Sign Below

compensation of our named executive officers, as disclosed in the Proxy Statement. For Against Abstain! ! !! ! ! Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. When signing in a fiduciary capacity, please indicate full title as such. If a corporation or partnership, please sign in full corporate or partnership name by authorized person.

officer.Signature [PLEASE SIGN WITHIN BOX]DateSignature (Joint Owners)Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature within


TABLE OF CONTENTS
[MISSING IMAGE: px_24sellasproxy1pg2-bw.jpg]
Important Notice Regarding the box. Signature 2 — Please keep signature withinAvailability of Proxy Materials for the box.

C 1234567890 J N T MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND

MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND

MMMMMMM1UP X 292041 1 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND +

02FMBA


LOGO

IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.

Annual Meeting:The Notice and Proxy — Galena Biopharma, Inc.

PROXY FOR SPECIALStatement and Annual Report are available at www.proxyvote.com.V42909-P10008SELLAS LIFE SCIENCES GROUP, INC.ANNUAL MEETING OF STOCKHOLDERS

THISSTOCKHOLDERSJune 20, 2024 at 8:30 a.m. Eastern TimeTHIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF GALENA BIOPHARMA, INC. AND MAY BE REVOKED BY THE STOCKHOLDER PRIOR TO ITS EXERCISE.

The undersigned stockholder of Galena Biopharma, Inc., a Delaware corporation, acknowledges receipt of the Notice of Special Meeting of StockholdersDIRECTORSThe stockholder(s) hereby appoint(s) Angelos M. Stergiou and Proxy Statement, each dated September 9, 2016. The undersigned stockholder hereby also designates Mark W. Schwartz, Ph.D. and Thomas J. Knapp,John T. Burns, or anyeither of them, as proxies, and attorneys-in-fact,each with fullthe power to each other of substitution, on behalfappoint his substitute, and in the name of the undersigned,hereby authorize(s) them to represent the undersigned at the Special Meeting of Stockholders of Galena Biopharma, Inc. to be held on Friday, October 21, 2016, at 9:00 a.m., local time, at 2010 Crow Canyon Place, Suite 130, San Ramon, California, 94583 and at any adjournment thereof, and to vote, as designated on the reverse side of this ballot, all of the shares of Common Stock whichof SELLAS LIFE SCIENCES GROUP, INC. that the undersigned would bestockholder(s) is/are entitled to vote if thenat the Annual Meeting of Stockholders to be held at 8:30 a.m. Eastern Time, on June 20, 2024, virtually at www.virtualshareholdermeeting.com/SLS2024, and there personally present,any adjournment or postponement thereof.This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors' recommendations.Continued and to be signed on the matters set forth on the reverse side.side

THIS PROXY WILL BE VOTED AS DIRECTED, OR IF NO CONTRARY DIRECTION IS INDICATED, WILL BE VOTED FOR PROPOSALS 1, 2 AND 3, AS SAID PROXIES (OR ANY OF THEM) DEEM ADVISABLE ON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE MEETING OR ANY POSTPONEMENT OR ADJOURNMENT THEREOF. THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSALS 1, 2 AND 3.

CONTINUED AND TO BE SIGNED ON REVERSE SIDE